Helicobacter pylori, хеликобактериоз и ассоциированные заболевания (VIII Московские соглашения по диагностике и лечению хеликобактериоза у взрослых и детей) Руководство для врачей

Настоящее руководство, суммирующее современный мировой и национальный опыт по диагностике и лечению хеликобактериоза, предназначено в первую очередь для практикующих врачей. Подготавливаемое в течение нескольких лет, оно направлено на расширение борьбы с этой непростой соматической инфекцией. Основной материал пособия представлен адаптированными разделами из современных научных исследований, клинических рекомендаций профильных обществ.

Helicobacter pylori, хеликобактериоз, диагностика, лечение, инфекция, ассоциированные заболевания, гастроэнтерология, клинические рекомендации, антибиотикорезистентность, эрадикационная терапия, воспалительные заболевания желудка, язвенная болезнь, рак желудка, микробиом, VIII Московские соглашения, взрослые, дети, руководство для врачей

1. Lazebnik L.B., Tkachenko E.I., Abdulganiyeva D.I. et al. VI National guidelines for the diagnosis and treatment of acid-related and helicobacter pylori-associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3-21. (In Russ.)@@ Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И. и соавт. VI национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017;(2):3-21.

2. Lazebnik L.B., Bordin D.S., Dekhnich N.N. et al. The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Memorandum. Experimental and Clinical Gastroenterology. 2021;(3):83-96. (In Russ.) doi: 10.31146/1682-8658-ecg-187-3-83-96.@@ Лазебник Л.Б., Бордин Д.С., Дехнич Н.Н. и Соавт. Необходимость усиления мер по диагностике и лечению хеликобактерной инфекции в России. Меморандум. Экспериментальная и клиническая гастроэнтерология. 2021;(3):83-96. doi: 10.31146/1682-8658-ecg-187-3-83-96.

3. Maev I. V., Andreev D.N., Samsonov A.A., Veliev A.M. Modern schemes of eradication therapy of infection helicobacter pylori: strategy of differentiated application, efficiency and safety. Experimental and Clinical Gastroenterology. 2017;140(4):103-110. (In Russ.)@@ Маев И.В., Андреев Д.Н., Самсонов А.А. и соавт. Современные схемы эрадикационной терапии инфекции Helicobacter pylori: стратегия дифференцированного применения, эффективность и безопасность. Экспериментальная и клиническая гастроэнтерология. 2017;140(4):103-110.

4. Lazebnik L.B., Bordin D.S., Dekhnich N.N., Kozlov R.S., Tryapyshko A.A.; Russian Scientific Medical Society of Therapists, Scientific Society of Gastroenterologists of Russia VII national guidelines for the diagnosis and treatment of diseases associated with Helicobacter pylori (VII Moscow Agreements) 2021. Available at: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2021/17102021_Project%20VII%20national%20recommendations%20for%20diagnosis%20and%20treatment%20of%20diseases%20associated%20with%20Helicobacter%20pylori.pdf (Accessed: 05.10.2024.)@@ Лазебник Л.Б., Бордин Д.С., Дехнич Н.Н., Козлов Р.С., Тряпышко А.А.; Российское научное медицинское общество терапевтов, Научное общество гастроэнтерологов России VII национальные рекомендации по диагностике и лечению заболеваний, ассоциированных с Helicobacter pylori (VII Московские соглашения) 2021. Электронный ресурс: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2021/17102021_Проект%20VII%20национальные%20рекомендации%20по%20диагностике%20и%20лечению%20заболеваний%20ассоциированных%20с%20Helicobacter%20pylori.pdf (Доступ: 05.10.2024.)

5. Bordin D.S., Livzan M.A., Osipenko M.F., Mozgovoy S.I., Andreyev D.N., Maev I.V. The key statements of the Maastricht VI consensus. Experimental and Clinical Gastroenterology. 2022;(9):5-21. (In Russ.) doi: 10.31146/1682-8658-ecg-205-9-5-21.@@ Бордин Д.С., Ливзан М.А., Осипенко М.Ф., Мозговой С.И., Андреев Д.Н., Маев И.В. Ключевые положения консенсуса Маастрихт VI. Экспериментальная и клиническая гастроэнтерология. 2022;(9):5-21. doi: 10.31146/1682-8658-ecg-205-9-5-21.

6. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014 Sep;19 Suppl 1:1-5. doi: 10.1111/hel.12165.

7. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol. 2011 May-Jun;45(5):383-8. doi: 10.1097/MCG.0b013e31820fb8f6.

8. Bordin D.S., Kuznetsova E.S., Stauver E.E., Nikol’skaya K.A., Chebotareva M.V., Voynovan I.N., Neyasova N.A. Epidemiology of Helicobacter pylori infection in the Russian Federation from 1990 to 2023: a systematic review. Russian Medical Inquiry. 2024;8(5):260-267 (in Russ.) doi: 10.32364/2587-6821-2024-8-5-3.@@ Бордин Д.С., Кузнецова Е.С., Стаувер Е.Е., Никольская К.А., Чеботарева М.В., Войнован И.Н., Неясова Н.А. Эпидемиология инфекции Helicobacter pylori в Российской Федерации с 1990 по 2023 г.: систематический обзор. РМЖ. Медицинское обозрение. 2024;8(5):260-267. doi: 10.32364/2587-6821-2024-8-5-3.

9. Lazebnik L.B., Vasil’ev Iu.V., Shcherbakov P.L. et al. [Helicobacter pylori: prevalence, diagnosis, treatment]. Eksp Klin Gastroenterol. 2010;(2):3-7. Russian. PMID: 20499451.@@ Лазебник Л.Б., Васильев Ю.В., Щербаков П.Л. и др. Helicobacter pylori: распространенность, диагностика, лечение. Экспериментальная и клиническая гастроэнтерология. 2010;2:3-7.

10. Abdulova M.S., Igonina N.A., Torshina I.G. et al. Evaluation of the estimated population prevalence of Helicobacter pylori infection and the frequency of achieving eradication after treatment based on the results of the 13C -urease breath test in individuals who applied to the federal network of the INVITRO laboratory (2019-2020, n=42,843). Experimental and Clinical Gastroenterology. 2021;(2):47-51. (In Russ.) doi: 10.31146/1682-8658-ecg-186-2-47-51.@@ Абдулова М.С., Игонина Н.А., Торшина И.Г. и др. Оценка ориентировочной популяционной распространенности инфекции Helicobacter pylori и частоты достижения эрадикации после лечения на основе результатов 13C -уреазного дыхательного теста у лиц, обратившихся в федеральную сеть лаборатории ИНВИТРО (2019-2020 гг., n=42843). Экспериментальная и клиническая гастроэнтерология. 2021;(2):47-51. doi: 10.31146/1682-8658- ecg-186-2-47.

11. Ivashkin V.T., Lapina T.L., Maev I.V. et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93. doi: 10.22416/1382-4376-2022-32-6-72-93.@@ Ивашкин В.Т., Лапина Т.Л., Маев И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93. doi: 10.22416/1382-4376-2022-32-6-72-93.

12. [The state of oncological care for the population of Russia in 2022]. edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow 2023. Available at: https://oncology-association.ru/wp-content/uploads/2023/08/sop-2022-el.versiya_compressed.pdf?ysclid=lzfcx9at1a847386652. (Accessed: 05.05.2024)@@ Состояние онкологической помощи населению России в 2022 году п/ред. А.Д. КАПРИНА, В.В. СТАРИНСКОГО, А.О. ШАХЗАДОВОЙ Москва 2023; https://oncology-association.ru/wp-content/uploads/2023/08/sop-2022- el.versiya_compressed.pdf?ysclid=lzfcx9at1a847386652.

13. Khatkov I.E., Abdulkhakov S.R., Alekseenko S.A. et al. Russian consensus on prevention, diagnosis and treatment of gastric cancer. Malignant tumours. 2023;13(2):56-68. (In Russ.) doi: 10.18027/2224-5057-2023-13-2-4.@@ Хатьков И.Е., Абдулхаков С.Р., Алексеенко С.А. и др. Российский консенсус по профилактике, диагностике и лечению рака желудка. Злокачественные опухоли. 2023;13(2):56-68. doi: 10.18027/2224-5057-2023-13-2-4.

14. Li N., Chen S., Xu X., et al. Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori. J Adv Res. Published online October 15, 2024. doi: 10.1016/j.jare.2024.10.012.

15. Malfertheiner P., Link A., Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):628-38. doi: 10.1038/nrgastro.2014.99.

16. Isaeva G. Sh., Valieva R.I. Biological characteristics and virulence of Helicobacter pylori. Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):14-23. (in Russ.) doi: 10.36488/cmac.2018.1.14-23.@@ Исаева Г.Ш., Валиева Р.И. Биологические свойства и вирулентность Helicobacter pylori. Клиническая микробиология и антимикробная химиотерапия. - 2018. - Т. 20. - № 1. - C. 14-23. doi: 10.36488/cmac.2018.1.14-23.

17. Andersen L.P., Rasmussen L. Helicobacter pylori-coccoid forms and biofilm formation. FEMS Immunol Med Microbiol. 2009 Jul;56(2):112-5. doi: 10.1111/j.1574-695X.2009.00556.x.

18. Gebel J., Vacata V., Sigler K., Pietsch H., Rechenburg A., Exner M., Kistemann T. Disinfectant activity against different morphological forms of Helicobacter pylori: first results. J Hosp Infect. 2001 Aug;48 Suppl A: S58-63. doi: 10.1016/s0195-6701(01)90016-7.

19. Suerbaum S. The complex flagella of gastric Helicobacter species. Trends Microbiol. 1995 May;3(5):168-70; discussion 170-1. doi: 10.1016/s0966-842x(00)88913-1.

20. Tomb J.F., White O., Kerlavage A.R. et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997 Aug 7;388(6642):539-47. doi: 10.1038/41483.

21. Falush D., Wirth T., Linz B. et al. Traces of human migrations in Helicobacter pylori populations. Science. 2003; 299(5612):1582-5. doi: 10.1126/science.1080857.

22. Linz B., Balloux F., Moodley Y. et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature. 2007; 445(7130):915-8. doi: 10.1038/nature05562.

23. Hussain S.A., Hamid S. Helicobacter pylori in humans: Where are we now? Adv Biomed Res. 2014 Jan 27;3:63. doi: 10.4103/2277-9175.125844.

24. Bustos-Fraga S., Salinas-Pinta M., Vicuña-Almeida Y., de Oliveira R.B., Baldeón-Rojas L. Prevalence of Helicobacter pylori genotypes: cagA, vacA (m1), vacA (s1), babA2, dupA, iceA1, oipA and their association with gastrointestinal diseases. A cross-sectional study in Quito-Ecuador. BMC Gastroenterol. 2023 Jun 6;23(1):197. doi: 10.1186/s12876-023-02838-9.

25. van Vliet A.H., Kuipers E.J., Waidner B. et al. Nickel-responsive induction of urease expression in Helicobacter pylori is mediated at the transcriptional level. Infect Immun. 2001 Aug;69(8):4891-7. doi: 10.1128/IAI.69.8.4891-4897.2001.

26. Stingl K., Altendorf K., Bakker E.P. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis? Trends Microbiol. 2002 Feb;10(2):70-4. doi: 10.1016/s0966-842x(01)02287-9.

27. Harris P.R., Mobley H.L., Perez-Perez G.I., Blaser M.J., Smith P.D. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. Gastroenterology. 1996 Aug;111(2):419-25. doi: 10.1053/gast.1996.v111.pm8690207.

28. Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014 Mar 12;15(3):306-16. doi: 10.1016/j.chom.2014.02.008.

29. Kao C.Y., Sheu B.S., Wu J.J. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J. 2016 Feb;39(1):14-23. doi: 10.1016/j.bj.2015.06.002.

30. Hussey S., Jones N.L. Helicobacter pylori in childhood. In: Saunders WB (ed) Pediatric gastrointestinal and liver disease. Elsevier, Amsterdam, 2011, pp 293-308.

31. Baj J., Forma A., Sitarz M., Portincasa P., Garruti G., Krasowska D., Maciejewski R. Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. Cells. 2020 Dec 25;10(1):27. doi: 10.3390/cells10010027.

32. McClain M.S., Beckett A.C., Cover T.L. Helicobacter pylori Vacuolating Toxin and Gastric Cancer. Toxins (Basel). 2017 Oct 12;9(10):316. doi: 10.3390/toxins9100316.

33. Román-Román A., Martínez-Carrillo D.N., Atrisco-Morales J. et al. Helicobacter pylori vacA s1m1 genotype but not cagA or babA2 increase the risk of ulcer and gastric cancer in patients from Southern Mexico. Gut Pathog. 2017 Apr 13;9:18. doi: 10.1186/s13099-017-0167-z.

34. Atherton J.C., Peek R.M. Jr, Tham K.T., Cover T.L., Blaser M.J. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 1997 Jan;112(1):92-9. doi: 10.1016/s0016-5085(97)70223-3.

35. Torres V.J., Ivie S.E., McClain M.S., Cover T.L. Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin. J Biol Chem. 2005 Jun 3;280(22):21107-14. doi: 10.1074/jbc.M501042200.

36. Shiota S., Suzuki R., Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013 Jul;14(7):341-9. doi: 10.1111/1751-2980.12054.

37. Matsuo Y, Kido Y, Yamaoka Y. Helicobacter pylori Outer Membrane Protein-Related Pathogenesis. Toxins (Basel). 2017 Mar 11;9(3):101. doi: 10.3390/toxins9030101.

38. Chaturvedi G., Tewari R., Mrigank., Agnihotri N., Vishwakarma R.A., Ganguly N.K. Inhibition of Helicobacter pylori adherence by a peptide derived from neuraminyl lactose binding adhesin. Mol Cell Biochem. 2001 Dec;228(1-2):83-9. doi: 10.1023/a:1013314604403.

39. Li Y., Choi H., Leung K., Jiang F., Graham D.Y., Leung W.K. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):553-564. doi: 10.1016/S2468-1253(23)00070-5.

40. Hooi J.K.Y., Lai W.Y., Ng W.K. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022.

41. Mezmale L., Coelho L.G., Bordin D., Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter. 2020 Sep;25 Suppl 1: e12734. doi: 10.1111/hel.12734.

42. Alberts C.J., Jeske R., de Martel C. et al. Helicobacter pylori seroprevalence in six different ethnic groups living in Amsterdam: The HELIUS study. Helicobacter. 2020 Jun;25(3): e12687. doi: 10.1111/hel.12687.

43. Chen Y.C., Malfertheiner P., Yu H.T. et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024 Apr;166(4):605-619. doi: 10.1053/j.gastro.2023.12.022.

44. Malfertheiner P., Camargo M.C., El-Omar E. et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023 Apr 20; 9(1):19. doi: 10.1038/s41572-023-00431-8.

45. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007.

46. Ivashkin V.T., Mayev I.V., Lapina T.L. et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol. 2018; 28(1):55-70. (in Russ.) doi: 10.22416/1382-4376-2018-28-1-55-70.@@ Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70.

47. Bordin D., Morozov S., Plavnik R. et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022 Oct;27(5): e12924. doi: 10.1111/hel.12924.

48. Bakulina N.V., Simanenkov V.I., Bakulin I.G., Ilchishina T.A. Prevalence of helicobacter pylori infection among physicians. Experimental and Clinical Gastroenterology. 2017;(12):20-24. (in Russ.)@@ Бакулина Н.В., Симаненков В.И., Бакулин И.Г., Ильчишина Т.А. Распространенность хеликобактерной инфекции среди врачей. Экспериментальная и клиническая гастроэнтерология. 2017;(12):20-24.

49. Bordin D.S., Plavnik R.G., Nevmerzhitskiy V.I. et al. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to ¹³С-urease breath test. Almanac of Clinical Medicine. 2018;46(1):40-49. (in Russ.) doi: 10.18786/2072-0505-2018-46-1-40-49.@@ Бордин Д.С., Плавник Р.Г., Невмержицкий В.И. и др. Распространенность Helicobacter pylori среди медицинских работников Москвы и Казани по данным ¹³С-уреазного дыхательного теста. Альманах клинической медицины. 2018;46(1):40-49. doi: 10.18786/2072-0505-2018-46-1-40-49.

50. Ivashkin V.T., Maev I.V., Lapina T.L. et al. H. pylori-Associated Gastritis, Gastritis after H. pylori Eradication and H. pylori-Negative Gastritis: Algorithm of Diagnosis and Treatment (Literature Review and Resolution of the Expert Panel of the Russian Gastroenterological Association). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(3):7-23. doi: 10.22416/1382-4376-2024-34-3-7-23.@@ Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. H. pylori-ассоциированный, постэрадикационный и негеликобактерный гастриты: алгоритм диагностики и лечения (обзор литературы и резолюция Совета экспертов Российской гастроэнтерологической ассоциации). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(3):7-23. doi: 10.22416/1382-4376-2024-34-3-7-23.

51. Kayali S., Manfredi M., Gaiani F. et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018 Dec 17;89(8-S):72-76. doi: 10.23750/abm.v89i8-S.7947.

52. FitzGerald R., Smith S.M. An Overview of Helicobacter pylori Infection. Methods Mol Biol. 2021;2283:1-14. doi: 10.1007/978-1-0716-1302-3_1.

53. Parente F., Maconi G., Sangaletti O., Minguzzi M., Vago L., Rossi E., Bianchi Porro G. Prevalence of Helicobacter pylori infection and related gastroduodenal lesions in spouses of Helicobacter pylori positive patients with duodenal ulcer. Gut. 1996 Nov;39(5):629-33. doi: 10.1136/gut.39.5.629.

54. Weyermann M., Rothenbacher D., Brenner H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol. 2009 Jan;104(1):182-9. doi: 10.1038/ajg.2008.61.

55. Rakhmanin Yu. A., German S.V. Prevalence and transmission pathways of the pyloric helicobacter infection. Transmission from person to person (Literature review). Hygiene and Sanitation. 2015;94(1):12-15. (in Russ.)@@ Рахманин Ю.А., Герман С.В. Распространенность и пути трансмиссии пилорической хеликобактерной инфекции. II. Трансмиссия инфекции из внешних источников (Обзор литературы). Гигиена и санитария. - 2015. - Т. 94. - № . 1. - С. 12-15.

56. Rusakov N.V., Bobrovnickiy I.P., German S.V., Rusakova E.V. Actual hygienic and epidemiological problems of helicobacteriosis. Hygiene and Sanitation. 2018;97(12):1179-1183. (In Russ.) doi: 10.47470/0016-9900-2018-97-12-1179-1183.@@ Русаков Н.В., Бобровницкий И.П., Герман С.В., Русакова Е.В. Актуальные гигиенические и эпидемиологические проблемы хеликобактериозов. Гигиена и санитария. 2018;97(12):1179-1183. doi: 10.47470/0016-9900-2018-97-12-1179-1183.

57. Yokota S., Konno M., Fujiwara S. et al. Intrafamilial, Preferentially Mother-to-Child and Intraspousal, Helicobacter pylori Infection in Japan Determined by Mutilocus Sequence Typing and Random Amplified Polymorphic DNA Fingerprinting. Helicobacter. 2015 Oct;20(5):334-42. doi: 10.1111/hel.12217.

58. Okuda M., Lin Y., Kikuchi S. Helicobacter pylori Infection in Children and Adolescents. Adv Exp Med Biol. 2019;1149:107-120. doi: 10.1007/5584_2019_361.

59. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252.

60. Mahachai V., Vilaichone R.K., Pittayanon R. et al. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan;33(1):37-56. doi: 10.1111/jgh.13911.

61. Xue Y., Zhou L.Y., Lu H.P., Liu J.Z. Recurrence of Helicobacter pylori infection: incidence and influential factors. Chin Med J (Engl). 2019 Apr 5;132(7):765-771. doi: 10.1097/CM9.0000000000000146.

62. Zhao J.B., Yuan L., Yu X.C. et al. Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis. Helicobacter. 2021 Jun;26(3): e12793. doi: 10.1111/hel.12793.

63. Kim M.S., Kim N., Kim S.E. et al. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter. 2013 Apr;18(2):135-42. doi: 10.1111/hel.12018.

64. Morgan D.R., Torres J., Sexton R. et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013 Feb 13;309(6):578-86. doi: 10.1001/jama.2013.311.

65. Yan T.L., Hu Q.D., Zhang Q., Li Y.M., Liang T.B. National rates of Helicobacter pylori recurrence are significantly and inversely correlated with human development index. Aliment Pharmacol Ther. 2013 May;37(10):963-8. doi: 10.1111/apt.12293.

66. Toh J.W.T., Wilson R.B. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals. Int J Mol Sci. 2020 Sep 3;21(17):6451. doi: 10.3390/ijms21176451.

67. Salama N.R., Hartung M.L., Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013 Jun;11(6):385-99. doi: 10.1038/nrmicro3016.

68. Yamaoka Y., Graham D.Y. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol. 2014 Jun;10(8):1487-500. doi: 10.2217/fon.14.29.

69. Sharndama H.C., Mba I.E. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022 Mar;53(1):33-50. doi: 10.1007/s42770-021-00675-0.

70. Dorer M.S., Talarico S., Salama N.R. Helicobacter pylori’s unconventional role in health and disease. PLoS Pathog. 2009 Oct;5(10): e1000544. doi: 10.1371/journal.ppat.1000544.

71. Zimmerman Ya.S. Eubiosis and dysbiosis of the gastrointestinal tract: myths and realities. Clinical medicine. 2013;91(1):4-11. (in Russ.)@@ Циммерман Я.С. Эубиоз и дисбиоз желудочно-кишечного тракта: мифы и реалии. Клиническая медицина. - 2013. - Т. 91. - № . 1. - С. 4-11.

72. Prada C.F., Casadiego M.A., Freire C.C. Evolution of Helicobacter spp: variability of virulence factors and their relationship to pathogenicity. Peer J. 2022 Aug 29;10: e13120. doi: 10.7717/peerj.13120.

73. Fox J.G. The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut. 2002 Feb;50(2):273-83. doi: 10.1136/gut.50.2.273.

74. Totten P.A., Fennell C.L., Tenover F.C. et al. Campylobacter cinaedi (sp. nov.) and Campylobacter fennelliae (sp. nov.): two new Campylobacter species associated with enteric disease in homosexual men. J Infect Dis. 1985 Jan;151(1):131-9. doi: 10.1093/infdis/151.1.131.

75. Matsumoto T., Goto M., Murakami H. et al. Multicenter study to evaluate bloodstream infection by Helicobacter cinaedi in Japan. J Clin Microbiol. 2007 Sep;45(9):2853-7. doi: 10.1128/JCM.00465-07.

76. Murakami H., Goto M., Ono E., Sawabe E., Iwata M., Okuzumi K., Yamaguchi K., Takahashi T. Isolation of Helicobacter cinaedi from blood of an immunocompromised patient in Japan. J Infect Chemother. 2003 Dec;9(4):344-7. doi: 10.1007/s10156-003-0265-3.

77. O’Rourke J.L., Grehan M., Lee A. Non-pylori Helicobacter species in humans. Gut. 2001 Nov;49(5):601-6. doi: 10.1136/gut.49.5.601.

78. Rasmussen S.L., Ørsted I., Tarpgaard I.H., Nielsen H.L. Helicobacter cinaedi bacteraemia secondary to enterocolitis in an immunocompetent patient. Gut Pathog. 2021 Apr 23;13(1):26. doi: 10.1186/s13099-021-00422-8.

79. Shakir S.M., Powers-Fletcher M.V., Slechta E.S., Fisher M.A. Helicobacter canis bacteraemia and cellulitis in a patient with end-stage renal disease. JMM Case Rep. 2017 Nov 8;4(11): e005126. doi: 10.1099/jmmcr.0.005126.

80. van der Vusse M.L., van Son W.J., Ott A., Manson W. Helicobacter canis bacteremia in a renal transplant patient. Transpl Infect Dis. 2014 Feb;16(1):125-9. doi: 10.1111/tid.12174.

81. Araoka H., Baba M., Kimura M., Abe M., Inagawa H., Yoneyama A. Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive. J Clin Microbiol. 2014 May;52(5):1519-22. doi: 10.1128/JCM.00265-14.

82. Sakoh T., Miyajima E., Endo Y. et al. Helicobacter fennelliae Localization to Diffuse Areas of Human Intestine, Japan. Emerg Infect Dis. 2024 Jan;30(1):129-132. doi: 10.3201/eid3001.231049.

83. Abd El-Ghany W.A. Helicobacter pullorum: A potential hurdle emerging pathogen for public health. J Infect Dev Ctries. 2020 Nov 30;14(11):1225-1230. doi: 10.3855/jidc.12843.

84. Ceelen L., Decostere A., Verschraegen G., Ducatelle R., Haesebrouck F. Prevalence of Helicobacter pullorum among patients with gastrointestinal disease and clinically healthy persons. J Clin Microbiol. 2005 Jun;43(6):2984-6. doi: 10.1128/JCM.43.6.2984-2986.2005.

85. Fox J.G., Dewhirst F.E., Shen Z. et al. Hepatic Helicobacter species identified in bile and lbladder tissue from Chileans with chronic cholecystitis. Gastroenterology. 1998 Apr;114(4):755-63. doi: 10.1016/s0016-5085(98)70589-x.

86. Laharie D., Asencio C., Asselineau J. et al. Association between entero-hepatic Helicobacter species and Crohn’s disease: a prospective cross-sectional study. Aliment Pharmacol Ther. 2009 Aug;30(3):283-93. doi: 10.1111/j.1365-2036.2009.04034.x.

87. Akhlaghi H., Javan A.J., Chashmi S.H.E. Helicobacter pullorum and Helicobacter canadensis: Etiology, pathogenicity, epidemiology, identification, and antibiotic resistance implicating food and public health. Int J Food Microbiol. 2024 Mar 2;413:110573. doi: 10.1016/j.ijfoodmicro.2024.110573.

88. Fox J.G., Chien C.C., Dewhirst F.E., Paster B.J., Shen Z., Melito P.L., Woodward D.L., Rodgers F.G. Helicobacter canadensis sp. nov. isolated from humans with diarrhea as an example of an emerging pathogen. J Clin Microbiol. 2000 Jul;38(7):2546-9. doi: 10.1128/JCM.38.7.2546-2549.2000.

89. Melito P.L., Munro C., Chipman P.R., Woodward D.L., Booth T.F., Rodgers F.G. Helicobacter winghamensis sp. nov., a novel Helicobacter sp. isolated from patients with gastroenteritis. J Clin Microbiol. 2001 Jul;39(7):2412-7. doi: 10.1128/JCM.39.7.2412-2417.2001.

90. Leemann C., Gambillara E., Prod’hom G. et al. First case of bacteremia and multifocal cellulitis due to Helicobacter canis in an immunocompetent patient. J Clin Microbiol. 2006 Dec;44(12):4598-600. doi: 10.1128/JCM.01453-06.

91. Mihevc M., Koren Krajnc M., Bombek Ihan M., Holc I. Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review. Ann Clin Microbiol Antimicrob. 2021 Apr 8; 20(1):22. doi: 10.1186/s12941-021-00426-x.

92. Murphy G., Freedman N.D., Abnet C.C. et al. Helicobacter hepaticus and Helicobacter bilis in liver and biliary cancers from ATBC and PLCO. Helicobacter. 2024 Jan-Feb;29(1): e13053. doi: 10.1111/hel.13053.

93. Osaki T., Lin Y., Sasahira N. et al. Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers. Helicobacter. 2022 Feb;27(1): e12866. doi: 10.1111/hel.12866.

94. Goji S., Tamura Y., Sasaki M. et al. Helicobacter suis-Infected Nodular Gastritis and a Review of Diagnostic Sensitivity for Helicobacter heilmannii-Like Organisms. Case Rep Gastroenterol. 2015 May 29;9(2):179-87. doi: 10.1159/000431169.

95. Banks M., Graham D., Jansen M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019 Sep;68(9):1545-1575. doi: 10.1136/gutjnl-2018-318126.

96. Meyer A.R., Goldenring J.R. Injury, repair, inflammation and metaplasia in the stomach. J Physiol. 2018 Sep;596(17):3861-3867. doi: 10.1113/JP275512.

97. Parygina M.N., Mozgovoy S.I. Gastric mucosal atrophy: from morphologic phenomenon to diagnostic pattern detection in the aspect of gastric cancer prediction. Scientific Bulletin of the Omsk State Medical University. 2021;1(1-2):214-222. (in Russ.)@@ Парыгина М.Н., Мозговой С.И. Атрофия слизистой оболочки желудка: от морфологического феномена к детекции диагностического паттерна в аспекте предикции рака желудка. Научный вестник Омского государственного медицинского университета. - 2021;1(1-2):214-222.

98. Rugge M., Pennelli G., Pilozzi E., Fassan M., Ingravallo G., Russo V.M., Di Mario F.; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Gastritis: the histology report. Dig Liver Dis. 2011 Mar;43 Suppl 4: S373-84. doi: 10.1016/S1590-8658(11)60593-8.

99. Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology. 2021 Oct;161(4):1325-1332.e7. doi: 10.1053/j.gastro.2021.06.078.

100. Kuipers E.J. Pernicious Anemia, Atrophic Gastritis, and the Risk of Cancer. Clin Gastroenterol Hepatol. 2015 Dec;13(13):2290-2. doi: 10.1016/j.cgh.2015.07.013.

101. Lenti M.V., Rugge M., Lahner E. et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020 Jul 9;6(1):56. doi: 10.1038/s41572-020-0187-8.

102. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;(157):301-10. PMID: 15055303.

103. Livzan M.A., Krolevets T.S., Mozgovoy S.I. et al. Autoimmune gastritis: from symptom to diagnosis. Clinical observations. Consilium Medicum. 2020; 22 (8): 78-84. (in Russ.) doi: 110.26442/20751753.2020.8.200037.@@ Ливзан М.А., Кролевец Т.С., Мозговой С.И. и др. Аутоиммунный гастрит: от симптома к диагнозу. Клинические наблюдения. Consilium Medicum. 2020; 22 (8): 78-84. doi: 10.26442/20751753.2020.8.200037.

104. Tsapyak T.A., Kliaritskaia I.L., Krivy V.V., Iskova I.A. Atrophic gastritis: focus on clinical significance. Crimean therapeutic journal. 2023;(2):50-55. (in Russ.)@@ Цапяк Т.А., Кляритская И.Л., Кривой В.В., Иськова И.А. Атрофический гастрит: фокус на клиническое значение. Крымский терапевтический журнал. 2023;(2):50-55.

105. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(10):1161-81. doi: 10.1097/00000478-199610000-00001.

106. Samloff I.M., Varis K., Ihamaki T., Siurala M., Rotter J.I. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982 Jul;83(1 Pt 2):204-9. PMID: 7084603.

107. Kishikawa H., Nakamura K., Ojiro K. et al. Relevance of pepsinogen, gastrin, and endoscopic atrophy in the diagnosis of autoimmune gastritis. Sci Rep. 2022 Mar 10;12(1):4202. doi: 10.1038/s41598-022-07947-1.

108. Rugge M., Correa P., Di Mario F. et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008 Aug;40(8):650-8. doi: 10.1016/j.dld.2008.02.030.

109. Robles C., Rudzite D., Polaka I. et al. Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment-Results from the GISTAR Pilot Study. Diagnostics (Basel). 2022 Jul 19;12(7):1746. doi: 10.3390/diagnostics12071746.

110. Ozhiganova N.V., Belkovets A.V., Kruchinina M.V. Early diagnosis of autoimmune gastritis. Experimental and Clinical Gastroenterology. 2023;(4):12-18. (In Russ.) doi: 10.31146/1682-8658-ecg-212-4-12-18.@@ Ожиганова Н.В., Белковец А.В., Кручинина М.В. Ранняя диагностика аутоиммунного гастрита. Экспериментальная и клиническая гастроэнтерология. 2023;(4):12-18. doi: 10.31146/1682-8658-ecg-212-4-12-18.

111. Liou J.M., Malfertheiner P., Lee Y.C. et al.; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368.

112. Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365-388. doi: 10.1055/a-0859-1883.

113. Woo J.S., el-Zimaity H.M., Genta R.M., Yousfi M.M., Graham D.Y. The best gastric site for obtaining a positive rapid ureas test. Helicobacter. 1996 Dec;1(4):256-9. doi: 10.1111/j.1523-5378.1996.tb00048.x.

114. Malfertheiner P. Diagnostic methods for H. pylori infection: Choices, opportunities and pitfalls. United European Gastroenterol J. 2015 Oct;3(5):429-31. doi: 10.1177/2050640615600968.

115. Logan R.P., Walker M.M. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ. 2001 Oct 20;323(7318):920-2. doi: 10.1136/bmj.323.7318.920.

116. Comparison of quantifying Helicobacter pylori gastric infection by culture, histology and13C urea breath test]. Gastroenterol Clin Biol. 1998 Apr;22(4):407-12. French. PMID: 9762270.

117. Lehours P., Mégraud F. Helicobacter pylori molecular diagnosis. Expert Rev Mol Diagn. 2011 May;11(4):351-5. doi: 10.1586/erm.11.17.

118. Miendje Deyi V.Y., Burette A., Bentatou Z. et al. Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis. 2011 Aug;70(4):557-60. doi: 10.1016/j.diagmicrobio.2011.05.002.

119. Lee J.W., Kim N., Nam R.H. et al. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. Scand J Gastroenterol. 2014 Sep;49(9):1058-67. doi: 10.3109/00365521.2014.894117.

120. Leodolter A., Domínguez-Muñoz J.E., von Arnim U., Kahl S., Peitz U., Malfertheiner P. Validity of a modified13C -urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol. 1999 Aug;94(8):2100-4. doi: 10.1111/j.1572-0241.1999.01284.x.

121. Nocon M., Kuhlmann A., Leodolter A., Roll S., Vauth C., Willich S.N., Greiner W. Efficacy and cost-effectiveness of the13C -urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technol Assess. 2009 Oct 21;5: Doc14. doi: 10.3205/hta000076.

122. Brandi G., Biavati B., Calabrese C. et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol. 2006 Aug;101(8):1756-61. doi: 10.1111/j.1572-0241.2006.00698.x.

123. Trevisani L., Sartori S., Galvani F. et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Am J Gastroenterol. 1999 Jul;94(7):1830-3. doi: 10.1111/j.1572-0241.1999.01213.x.

124. Choi J., Kim C.H., Kim D. et al. Prospective evaluation of a new stool antigen test for the detection of Helicobacter pylori, in comparison with histology, rapid urease test, (13) C-urea breath test, and serology. J Gastroenterol Hepatol. 2011 Jun;26(6):1053-9. doi: 10.1111/j.1440-1746.2011.06705.x.

125. Chehter E.Z., Bacci M.R., Fonseca F.L. et al. Diagnosis of the infection by the Helicobacter pylori through stool examination: method standardization in adults. Clin Biochem. 2013 Oct;46(15):1622-4. doi: 10.1016/j.clinbiochem.2013.05.071.

126. Ivashkin V.T., Maev I.V., Gorgun J.V. et al. Pathogenetic Treatment of Gastritis as a Basis for the Prevention of Gastric Cancer in the Countries of the Commonwealth of Independent States: Literature Review and the Resolution of a Scientific Symposium Held in Minsk, Republic of Belarus, January, 27, 2018. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(4):7-14. (In Russ.) doi: 10.22416/1382-4376-2018-28-4-7-14.@@ Ивашкин В.Т., Маев И.В., Горгун Ю.В. и др. Патогенетическое лечение гастрита как основа профилактики рака желудка в странах - членах Содружества Независимых Государств (Обзор литературы и резолюция научного симпозиума 27.01.2018, г. Минск, Республика Беларусь). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(4):7-14. doi: 10.22416/1382-4376-2018-28-4-7-14.

127. Karateyev A. Ye., Moroz Ye.V., Tsurgan A.V., Gontarenko N.V. Is Helicobacter pylori eradication required for non-steroidal anti-inflammatory drug-associated erosions and ulcers? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(6):5-17. (In Russ.) doi: 10.22416/1382-4376-2016-6-5-17.@@ Каратеев А.Е., Мороз Е.В., Цурган А.В., Гонтаренко Н.В. Нужно ли проводить эрадикацию Helicobacter pylori у больных с эрозиями и язвами, возникшими на фоне терапии нестероидными противовоспалительными препаратами? Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(6):5-17. doi: 10.22416/1382-4376-2016-6-5-17.

128. Ford A.C., Forman D., Hunt R.H., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014 May 20;348: g3174. doi: 10.1136/bmj.g3174.

129. Lee Y.C., Chiang T.H., Chou C.K., Tu Y.K., Liao W.C., Wu M.S., Graham D.Y. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 May;150(5):1113-1124.e5. doi: 10.1053/j.gastro.2016.01.028.

130. Malfertheiner P., Megraud F., O’Morain C.A. et al.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288.

131. Sugano K., Tack J., Kuipers E.J. et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252.

132. Malfertheiner P., Megraud F., Rokkas T. et al.; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8: gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745.

133. Espada M., Nyssen O.P., Gisbert J.P. Empirical versus susceptibility-guided treatment of Helicobacter pylori infection: a meta-analysis. United European Gastroenterol J. 2020;8:251.

134. Mayev I.V., Andreyev D.N., Bordin D.S. et al. Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effective pharmacotherapy. 2020;16(30):16-22. (In Russ.)@@ Маев И.В., Андреев Д.Н., Бордин Д.С. и соавт. Резистентность Helicobacter pylori к кларитромицину в Российской Федерации. Эффективная фармакотерапия. 2020;16(30):16-22.

135. Andreev D.N., Maev I.V., Kucheryavyy Yu.A. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Therapeutic archive. 2020;92(11):24-30. (In Russ.)@@ Андреев Д.Н., Маев И.В., Кучерявый Ю.А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020;92(11):24-30.

136. Ding S.Z. Global whole family based-Helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer. World J Gastroenterol. 2020 Mar 14;26(10):995-1004. doi: 10.3748/wjg.v26.i10.995.

137. Simadibrata D.M., Syam A.F., Lee Y.Y. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 Dec;37(12):2217-2228. doi: 10.1111/jgh.16017.

138. Alkim H., Koksal A.R., Boga S., Sen I., Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2017 Nov/Dec;24(6): e751-e757. doi: 10.1097/MJT.0000000000000389.

139. Nyssen O.P., Moreira L., García-Morales N. et al. European Registry on Helicobacter pylori Management (Hp-EuReg): Most relevant results for clinical practice. Frontiers in Gastroenterology. 2022;(1):14.

140. Simanenkov V. I., Bakulina N.V., Fil T.S., Khubieva A.Kh. Evaluation of efficiency of H. Pylori eradication in case of addition of cytoprotective preparation rebamipide to the treatment: results of the BASTION trial. Pharmateka. 2017; (S5): 65-71. (in Russ.)@@ Симаненков В.И., Бакулина Н.В., Филь Т.С., Хубиева А.Х. Оценка эффективности эрадикации H. pylori при добавлении к схеме лечения цитопротективного препарата ребамипид: результаты исследования БАСТИОН. Фарматека. 2017;(S5):65-71.

141. Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):940-956. (in Russ.) doi: 10.26442/00403660.2022.08.201523.@@ Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022;94(8):940-956. doi: 10.26442/00403660.2022.08.201523.

142. Andreev D.N., Maev I.V., Dicheva D.T. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. doi: 10.3390/jcm8091498.

143. Nishizawa T., Nishizawa Y., Yahagi N., Kanai T., Takahashi M., Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014; 29(4):20-24. doi:10.1111/jgh.12769.

144. Lazebnik L.B., Belousova N.L., Bordin D.S. et al. Resistance of Helicobacter pylori to clarithromycin in Moscow and propolis as a means of increasing the effectiveness of eradication. Experimental and Clinical Gastroenterology. 2012;(8):10-14. (in Russ.)@@ Лазебник Л.Б., Белоусова Н.Л., Бордин Д.С. и соавт. Резистентность Helicobacter pylori к кларитромицину в Москве и прополис как средство, повышающее эффективность эрадикации. Экспериментальная и клиническая гастроэнтерология. 2012;(8):10-14.

145. Buckley M., Lacey S., Doolan A., Goodbody E., Seamans K. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutr. 2018 Dec 7;4:48. doi: 10.1186/s40795-018-0257-4.

146. Mehling H., Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013 Aug 2;5(8):3062-73. doi: 10.3390/nu5083062.

147. Yang C., Liang L., Lv P., Liu L., Wang S., Wang Z., Chen Y. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter. 2021 Dec;26(6): e12856. doi: 10.1111/hel.12856.

148. Bordin D.S., Voynovan I.N., Khomeriki S.G., Yanova O.B., Kim V.A., Bystrovskaya E.V., Shishin K.V. Efficiency and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori. Lvrach.ru. 2016;5:106-110.@@ Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus reuteri DSM17648 у инфицированных Helicobacter pylori. Лечащий врач. 2016;5:106-110.

149. Uspenskiy Yu.P., Fomin Yu. A., Ivanov S.V., Menaker I.O. Evolution in eradication therapy of HP -associated diseases: beyond the standards? RMJ. 2016;(17):1144-1152. (in Russ.)@@ Успенский Ю.П., Фоминых Ю.А., Иванов С.В., Менакер И.О. Эволюция в эрадикационной терапии НР-ассоциированных заболеваний. Выход за рамки стандартов? РМЖ. 2016;(17):1144-1152.

150. hlynov I. B., Akimenko R.I., Voronova E.I. et al. Possible role of Lactobacillus reuteri for eradication of Helicobacter pylori in adults in real clinical practice. Lvrach.ru. 2020;(2):19-22. (in Russ.) doi: 10.26295/OS.2020.45.81.004.@@ Хлынов И.Б., Акименко Р.И., Воронова Е.И. и др. Роль Lactobacillus reuteri DSM17648 в эрадикационной терапии инфекции Helicobacter pylori у взрослых в реальной клинической практике. Лечащий врач. 2020;(2):19-22. doi: 10.26295/OS.2020.45.81.004.

151. Dekhnich N.N., Tryapyshko A.A., Trushin I.V., Kuzmenkov A.Yu., Kozlov R.S. Results of an open-label, randomized, comparative clinical trial of nifuratel in the eradication of Helicobacter pylori infection in adult patients. Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(2):119-127. (in Russ.)@@ Дехнич Н.Н., Тряпышко А.А., Трушин И.В., Кузьменков А.Ю., Козлов Р.С. Нифурател в эрадикации инфекции Helicobacter pylori у взрослых: результаты рандомизированного сравнительного клинического исследования. Клиническая микробиология и антимикробная химиотерапия. 2020; 22(2):119-127.

152. Vasilevsky I.V. New approaches to Helicobacter pylori eradication using nifuroxazide. International Reviews: Clinical Practice and Health. 2013;(1):8-14. (in Russ.)@@ Василевский И.В. Новые подходы к эрадикации Helicobacter pylori с использованием нифуроксазида. Международные Обзоры: клиническая практика и здоровье, 2013;(1):8-14.

153. Ierardi E., Losurdo G., Mileti A. et al. The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science. Antibiotics (Basel). 2020 May 31;9(6):293. doi: 10.3390/antibiotics9060293.

154. Ormeci A., Emrence Z., Baran B. et al. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism? Eur Rev Med Pharmacol Sci. 2016 May;20(9):1795-7. PMID: 27212172.

155. Kareva E.N. Pharmacogenetic management concerning efficacy and safety of proton-pump inhibitors. RMJ. 2021;4:68-73. (in Russ.)@@ Карева Е.Н. Фармакогенетическое управление эффективностью и безопасностью ингибиторов протонных помп. РМЖ. 2021;4:68-73.

156. Lima J.J., Thomas C.D., Barbarino J. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423. doi: 10.1002/cpt.2015.

157. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther. 2004 Nov;20 Suppl 6:11-9. doi: 10.1111/j.1365-2036.2004.02161.x.

158. Abelö A., Andersson T.B., Antonsson M., Naudot A.K., Skånberg I., Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Aug;28(8):966-72. PMID: 10901708.

159. Sahara S., Sugimoto M., Uotani T. et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. doi: 10.1111/apt.12492.

160. Li X.Q., Andersson T.B., Ahlström M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821.

161. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006 Nov;4(11):2508-9. doi: 10.1111/j.1538-7836.2006.02162.x.

162. Focks J.J., Brouwer M.A., van Oijen M.G., Lanas A., Bhatt D.L., Verheugt F.W. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. 2013 Apr;99(8):520-7. doi: 10.1136/heartjnl-2012-302371.

163. Blanco Dorado S., Maroñas Amigo O., Latorre-Pellicer A. et al. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. Br J Clin Pharmacol. 2020 Aug;86(8):1661-1666. doi: 10.1111/bcp.14267.

164. Cytochrome P-450 CYP2C9 substrates. The DrugBank database. Available at: https://www.drugbank.ca/categories/DBCAT002634 (Accessed: 30.03.2020).

165. Hunt R., Lazebnik L.B., Marakhouski Y.C., et al. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian J Hepatogastroenterol. 2018 Jul-Dec;8(2):148-160. doi: 10.5005/jp-journals-10018-1281.

166. Elwood P., Protty M., Morgan G., Pickering J., Delon C., Watkins J. Aspirin and cancer: biological mechanisms and clinical outcomes. Open Biol. 2022 Sep;12(9):220124. doi: 10.1098/rsob.220124.

167. Zhang X., Feng Y., Liu X., Ma J., Li Y., Wang T., Li X. Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. J Cancer Res Clin Oncol. 2019 Jun;145(6):1387-1403. doi: 10.1007/s00432-019-02902-6.

168. Patrignani P., Patrono C. Aspirin and Cancer. J Am Coll Cardiol. 2016 Aug 30;68(9):967-76. doi: 10.1016/j.jacc.2016.05.083.

169. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998 May 29;93(5):705-16. doi: 10.1016/s0092-8674(00)81433-6.

170. Dovizio M., Alberti S., Guillem-Llobat P., Patrignani P. Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):118-27. doi: 10.1111/bcpt.12156.

171. Li P., Ning Y., Li M. et al. Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):456-465. doi: 10.1177/1074248420925021.

172. Cheung K.S., Li B., Wong I.Y., Law S., Leung W.K. Benefit and Harm of Aspirin on Mortality From Gastrointestinal Cancers Vs Bleeding in Helicobacter pylori-Eradicated Patients. Clin Gastroenterol Hepatol. 2024 Sep;22(9):1810-1820. doi: 10.1016/j.cgh.2024.05.003.

173. Moayyedi P., Eikelboom J.W., Bosch J. et al.; COMPASS Investigators. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019 Aug;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041.

174. Jankowski J.A.Z., de Caestecker J., Love S.B. et al.; AspECT Trial Team. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018 Aug 4;392(10145):400-408. doi: 10.1016/S0140-6736(18)31388-6.

175. Moayyedi P., Armstrong D., Hunt R.H., Lei Y., Bukoski M., White R.J. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS - a cluster-randomized trial. Am J Gastroenterol. 2010 Nov;105(11):2341-6. doi: 10.1038/ajg.2010.368.

176. Maev I.V., Samsonov A.A., Andreev N.G., Kochetov S.A. Clarithromycin as the main element of eradication therapy of diseases associated with Helicobacter infection. Gastroenterology. 2011;(1):88-93. (in Russ.)@@ Маев И.В., Самсонов А.А., Андреев Н.Г., Кочетов С.А. Кларитромицин как основной элемент эрадикационной терапии заболеваний, ассоциированных с хеликобактерной инфекцией. Гастроэнтерология. 2011;(1):88-93.

177. Zanichelli V., Sharland M., Cappello B. et al. The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance. Bull World Health Organ. 2023 Apr 1;101(4):290-6. doi: 10.2471/BLT.22.288614.

178. Maev I.V., Andreev D.N., Bordin D.S. et al. Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effective Pharmacotherapy. 2020;16(30):16-22. (in Russ.) doi: 10.33978/2307-3586-2020-16-30-16-22.@@ Маев И.В., Андреев Д.Н., Бордин Д.С. и др. Резистентность Helicobacter pylori к кларитромицину в Российской Федерации. Эффективная фармакотерапия. 2020;16(30):16-22. doi: 10.33978/2307-3586-2020-16-30-16-22.

179. Andreev D.N., Maev I.V., Kucheryavyy Y.A. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Therapeutic Archive. 2020; 92 (11): 24-30. (in Russ.) doi: 10.26442/00403660.2020.11.000795.@@ Андреев Д.Н., Маев И.В., Кучерявый Ю.А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020; 92 (11): 24-30. doi: 10.26442/00403660.2020.11.000795.

180. De Francesco V., Margiotta M., Zullo A. et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006 Jan 17;144(2):94-100. doi: 10.7326/0003-4819-144-2-200601170-00006.

181. Francesco V.D., Zullo A., Hassan C., Giorgio F., Rosania R., Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol. 2011 Jun 15;2(3):35-41. doi: 10.4291/wjgp.v2.i3.35.

182. Hirata K., Suzuki H., Nishizawa T. et al. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol. 2010 May;25 Suppl 1: S75-9. doi: 10.1111/j.1440-1746.2009.06220.x.

183. Iwamoto A., Tanahashi T., Okada R. et al. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog. 2014 Jun 26;6:27. doi: 10.1186/1757-4749-6-27.

184. Tsugawa H., Suzuki H., Muraoka H., Ikeda F., Hirata K., Matsuzaki J., Saito Y., Hibi T. Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori. Biochem Biophys Res Commun. 2011 Jan 14;404(2):656-60. doi: 10.1016/j.bbrc.2010.12.034.

185. van Amsterdam K., Bart A., van der Ende A. A Helicobacter pylori TolC efflux pump confers resistance to metronidazole. Antimicrob Agents Chemother. 2005 Apr;49(4):1477-82. doi: 10.1128/AAC.49.4.1477-1482.2005.

186. Gerrits M.M., van Vliet A.H., Kuipers E.J., Kusters J.G. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006 Nov;6(11):699-709. doi: 10.1016/S1473-3099(06)70627-2.

187. Gerrits M.M., Berning M., Van Vliet A.H., Kuipers E.J., Kusters J.G. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003 Sep;47(9):2984-6. doi: 10.1128/AAC.47.9.2984-2986.2003.

188. Gerrits M.M., de Zoete M.R., Arents N.L., Kuipers E.J., Kusters J.G. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002 Sep;46(9):2996-3000. doi: 10.1128/AAC.46.9.2996-3000.2002.

189. Tankovic J., Lascols C., Sculo Q., Petit J.C., Soussy C.J. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003 Dec;47(12):3942-4. doi: 10.1128/AAC.47.12.3942-3944.2003.

190. Kwon D.H., Lee M., Kim J.J., Kim J.G., El-Zaatari F.A., Osato M.S., Graham D.Y. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother. 2001 Jan;45(1):306-8. doi: 10.1128/AAC.45.1.306-308.2001.

191. Kunin C.M. Antimicrobial activity of rifabutin. Clin Infect Dis. 1996 Apr;22 Suppl 1: S3-13; discussion S13-4. doi: 10.1093/clinids/22.supplement_1.s3.

192. Ge R., Chen Z., Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012 Mar;4(3):239-43. doi: 10.1039/c2mt00180b.

193. Keogan D.M., Griffith D.M. Current and potential applications of bismuth-based drugs. Molecules. 2014 Sep 23;19(9):15258-97. doi: 10.3390/molecules190915258.

194. Zhang L., Mulrooney S.B., Leung A.F., Zeng Y., Ko B.B., Hausinger R.P., Sun H. Inhibition of urease by bismuth(III): implications for the mechanism of action of bismuth drugs. Biometals. 2006 Oct;19(5):503-11. doi: 10.1007/s10534-005-5449-0.

195. Jin L., Szeto K.Y., Zhang L., Du W., Sun H. Inhibition of alcohol dehydrogenase by bismuth. J Inorg Biochem. 2004 Aug;98(8):1331-7. doi: 10.1016/j.jinorgbio.2004.03.016.

196. Chiang T.H., Chen C.C., Tseng P.H., Liou J.M., Wu M.S., Shun C.T., Lee Y.C., Graham D.Y. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter. 2021 Jun;26(3): e12801. doi: 10.1111/hel.12801.

197. Liao J., Zheng Q., Liang X., Zhang W., Sun Q., Liu W., Xiao S., Graham D.Y., Lu H. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013 Oct;18(5):373-7. doi: 10.1111/hel.12052.

198. Casas D. et al. Patrón de prescripción de probióticos adyuvantes a la terapia erradicadora frente a Helicobacter pylori: resultados del registro europeo sobre el manejo de la infección por Helicobacter pylori (HP-EUREG) // Gastroenterología y hepatología: 26. ª Reunión Anual de la Asociación Españolade Gastroenterología: Madrid, 29-31 de marzo 2023: contenidos del congreso/Asociación Española de Gastroenterología. Madrid: Elsevier España, 2023, vol. 46, suppl. 3. - 2023.

199. World Gastroenterology Organisation Global Guidelines Probiotics and prebiotics. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pdf accessed: 05.09.2024.

200. Yu M., Zhang R., Ni P., Chen S., Duan G. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials. PLoS One. 2019 Oct 2;14(10): e0223309. doi: 10.1371/journal.pone.0223309.

201. Hauser G., Salkic N., Vukelic K., JajacKnez A., Stimac D. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2015 May;94(17): e685. doi: 10.1097/MD.0000000000000685.

202. Seddik H., Boutallaka H., Elkoti I. et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019 May;75(5):639-645. doi: 10.1007/s00228-019-02625-0.

203. Nista E.C., Candelli M., Cremonini F. et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1181-8. doi: 10.1111/j.1365-2036.2004.02274.x.

204. Plomer M., Iii Perez M., Greifenberg D.M. Effect of Bacillus clausii Capsules in Reducing Adverse Effects Associated with Helicobacter pylori Eradication Therapy: A Randomized, Double-Blind, Controlled Trial. Infect Dis Ther. 2020 Dec;9(4):867-878. doi: 10.1007/s40121-020-00333-2.

205. Bekar O., Yilmaz Y., Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food. 2011 Apr;14(4):344-7. doi: 10.1089/jmf.2010.0099.

206. Viazis N., Argyriou K., Kotzampassi K. et al. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients. 2022 Feb 1;14(3):632. doi: 10.3390/nu14030632.

207. Ermolenko E.I., Molostova A.S., Gladyshev N.S. Eradication therapy of helicobacteriosis with probiotics, problems, and prospects. Experimental and Clinical Gastroenterology. 2021;(9):60-72. (In Russ.) doi: 10.31146/1682-8658-ecg-193-9-60-72.@@ Ермоленко Е.И., Молостова А.С., Гладышев Н.С. Эрадикационная терапия хеликобактериоза при помощи пробиотиков: проблемы и перспективы. Экспериментальная и клиническая гастроэнтерология. 2021;(9):60-72.

208. Kononova A.G., Kolbasnikov S.V., Beldiev S.N. The role of probiotics in Helicobacter pylori eradication therapy regimens: current evidence of eff ectiveness. Experimental and Clinical Gastroenterology. 2022;(4):160-168. (In Russ.) doi: 10.31146/1682-8658-ecg-200-4-160-168.@@ Кононова А.Г., Колбасников С.В., Бельдиев С.Н. Роль пробиотиков в схемах эрадикационной терапии Helicobacter pylori: современные доказательства эффективности. Экспериментальная и клиническая гастроэнтерология. 2022;(4):160-168. doi: 10.31146/1682-8658-ecg-200-4-160-168.

209. Osipenko M.F., Zhuk E.A., Drobysheva V.P., Litvinova N.V., Livzan M.A., Gaus O.V. Probiotics in the Helicobacter pylori eradication therapy. Russian Medical Inquiry. 2023;7(5):274-282 (in Russ.) doi: 10.32364/2587-6821-2023-7-5-5.@@ Осипенко М.Ф., Жук Е.А., Дробышева В.П., Литвинова Н.В., Ливзан М.А., Гаус О.В. Место пробиотиков в эрадикационной терапии хеликобактерной инфекции. РМЖ. Медицинское обозрение. 2023;7(5):274-282. doi: 10.32364/2587-6821-2023-7-5-5.

210. Eslami M., Yousefi B., Kokhaei P. et al. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019 Jun;64:99-108. doi: 10.1016/j.cimid.2019.02.010.

211. Chen C.C., Liou J.M., Lee Y.C., Hong T.C., El-Omar E.M., Wu M.S. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021 Jan-Dec;13(1):1-22. doi: 10.1080/19490976.2021.1909459.

212. Parth K., Prudhivi R., Palatheeya S. et al. Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy. Journal of Pharmaceutical Research International. 2021;33(52B):151-159. doi: 10.9734/jpri/2021/v33i52B33611.

213. Liang B., Yuan Y., Peng X.J., Liu X.L., Hu X.K., Xing D.M. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol. 2022 Nov 25;12:1042070. doi: 10.3389/fcimb.2022.1042070.

214. Nanghibzadeh N., Salmani F., Nomiri S., Tavakoli T. Investigating the Effect of Quadruple Therapy with Saccharomyces Boulardii or Lactobacillus Reuteri Strain (DSMZ 17648) Supplements on Eradication of Helicobacter Pylori and Treatments Side Effects: A Double-Blind Placebo-Controlled Randomized Clinical Trial. Research Gate. doi: 10.21203/rs.3.rs-910711/v1.

215. Zhang L., Zhao M., Fu X. Gastric microbiota dysbiosis and Helicobacter pylori infection. Front Microbiol. 2023 Mar 30;14:1153269. doi: 10.3389/fmicb.2023.1153269.

216. Li Y., He C., Lu N. Impacts of Helicobacter pylori infection and eradication on gastrointestinal microbiota: An up-to-date critical review and future perspectives. Chin Med J (Engl). 2024 Dec 5;137(23):2833-2842. doi: 10.1097/CM9.0000000000003348.

217. Peddle S.D., Hodgson R.J., Borrett R.J. et al. Practical applications of soil microbiota to improve ecosystem restoration: current knowledge and future directions. Biol Rev Camb Philos Soc. 2025 Feb;100(1):1-18. doi: 10.1111/brv.13124.

218. Kesavelu D., Jog P. Current understanding of antibiotic-associated dysbiosis and approaches for its management. Ther Adv Infect Dis. 2023 Feb 24;10:20499361231154443. doi: 10.1177/20499361231154443.

219. Yu X., Jin Y., Zhou W. et al. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front Cell Infect Microbiol. 2022 Jan 18;11:761192. doi: 10.3389/fcimb.2021.761192.

220. Bajaj J.S., Ng S.C., Schnabl B. Promises of microbiome-based therapies. J Hepatol. 2022 Jun;76(6):1379-1391. doi: 10.1016/j.jhep.2021.12.003.

221. Gasbarrini A., Lauritano E.C., Nista E.C. et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis. 2006;24(1-2):195-200. doi: 10.1159/000090330.

222. Gasbarrini A., Gasbarrini G., Pelosini I., Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion. 2006;73 Suppl 1:129-35. doi: 10.1159/000089788.

223. Wang Y., Tang J., Zhou S., Liang T.T., Wang F.F., Ning H. Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review - Are They Potential Eradication Regimens? Infect Drug Resist. 2022 Jul 13;15:3733-3749. doi: 10.2147/IDR.S371131.

224. Ke S., Weiss S.T., Liu Y.Y. Rejuvenating the human gut microbiome. Trends Mol Med. 2022 Aug;28(8):619-630. doi: 10.1016/j.molmed.2022.05.005.

225. Ong I. J., Loo K.-Y., Law L.N.-S. et al. Exploring the Impact of Helicobacter pylori and Potential Gut Microbiome Modulation. Progress In Microbes & Molecular Biology. 2023;6(1). doi: 10.36877/pmmb.a0000273.

226. Liou J.M., Chen C.C., Chang C.M. et al.; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019 Oct;19(10):1109-1120. doi: 10.1016/S1473-3099(19)30272-5.

227. Jiang Y., Zhang R., Fang Y. et al. P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. Therap Adv Gastroenterol. 2024 May 14;17:17562848241241223. doi: 10.1177/17562848241241223.

228. Liang J.W., Xiong S., Jia Y.G. et al. Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial. J Gastroenterol Hepatol. 2024 Nov;39(11):2293-2298. doi: 10.1111/jgh.16679.

229. Park C.H., Song M.J., Jung B.W., Park J.H., Jung Y.S. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. J Pers Med. 2022 Nov 17;12(11):1918. doi: 10.3390/jpm12111918.

230. Jung Y.S., Kim S., Kim H.Y., Noh S.J., Park J.H., Park C.H. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol. 2022 Oct;37(10):1911-1918. doi: 10.1111/jgh.15939.

231. Jung Y.S., Kim S., Kim H.Y., Noh S.J., Park J.H., Sohn C.I., Park C.H. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study. Gut Liver. 2023 Sep 15;17(5):711-721. doi: 10.5009/gnl220218.

232. Cho J.H. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. Expert Rev Anti Infect Ther. 2024 Sep;22(9):793-799. doi: 10.1080/14787210.2024.2329251.

233. Lee J.W., Kim N., Nam R.H., Yu J.E., Son J.H., Lee S.M., Lee D.H. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori. Gut Liver. 2021 Jan 15;15(1):53-60. doi: 10.5009/gnl20247.

234. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013 Jun;42(2):211-7. doi: 10.1016/j.gtc.2013.01.002.

235. Livzan M.A., Gauss O.V., Mozgovoy S.I. Chronic atrophic gastritis: tactics of patient curation. breast cancer. Medical review. 2021;5(6):427-432. (in Russ.) doi: 10.32364/2587-6821-2021-5-6-427-432.@@ Ливзан М.А., Гаус О.В., Мозговой С.И. Хронический атрофический гастрит: тактика курации пациента. РМЖ. Медицинское обозрение. 2021; 6: 427-432. doi: 10.32364/2587-6821-2021-5-6-427-432.

236. International Agency for Research on Cancer. IARC (1994) Schistosomes, Liver Flukes and Helicobacter Pylori (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61), Lyon, IARC Available at: https://www.iarc.who.int/world-cancer-report-content-overview/ (Accessed 21.03.2024).

237. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun;56(6):772-81. doi: 10.1136/gut.2006.101634.

238. Niv Y., Rokkas T. MUC1 expression in the gastric mucosa of Helicobacter pylori positive gastritis - A systematic review and meta-analysis. Microb Health Dis. 2023; 5: e952. doi: 10.26355/mhd_202311_952.

239. Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi: 10.15829/1728-8800-2021-2758.@@ Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi: 10.15829/1728-8800-2021-2758.

240. Lapina Т.L., Ivashkin V.T. Rebamipide during chronic gastritis: H. pylori eradication therapy and restoration of gastric mucosa barrier function. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):81-87. doi: 10.22416/1382-4376-2023-33-6-81-87.@@ Лапина Т.Л., Ивашкин В.Т. Ребамипид при хроническом гастрите: эрадикационная терапия H. pylori и восстановление барьерной функции слизистой оболочки желудка. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(6):81-87. doi: 10.22416/1382-4376-2023-33-6-81-87.

241. Andreev D.N., Maev I.V. Rebamipide: evidence base for use in gastroenterology. Therapeutic Archive. 2020; 92 (12): 97-104. (in Russ.) doi: 10.26442/00403660.2020. 12.200455.@@ Андреев Д.Н., Маев И.В. Ребамипид: доказательная база применения в гастроэнтерологии. Терапевтический архив. 2020; 92 (12): 97-104. doi: 10.26442/00403660.2020.12.200455.

242. Ostroumova O.D., Kochetkov A.I., Batyukina S.V., Cheremushkin S.V. Gastroprotective therapy in patients with atrial fibrillation receiving anticoagulant therapy: A review. Consilium Medicum. 2023;25(5):368-374. (in Russ.) doi: 10.26442/20751753.2023.5.202294.@@ Остроумова О.Д., Кочетков А.И., Батюкина С.В., Черемушкин С.В. Гастропротективная терапия у пациентов с фибрилляцией предсердий, получающих антикоагулянтную терапию. Consilium Medicum. 2023;25(5):368-374. doi: 10.26442/20751753.2023.5.202294.

243. Ratnikova A., Grinevich V., Ratnikov V. et al. Significance of indicators of intestinal permeability, the state of the microbiota in the development of gastroenterological manifestations in the treatment of patients with a new coronavirus infection (COVID-19). Vrach. 2022; 33 (1): 80-88. (in Russ.) doi: 10.29296/25877305-2022-01-14.@@ Ратникова А.К., Гриневич В.Б., Ратников В.А. и др. Значение показателей кишечной проницаемости, состояния микробиоты в развитии гастроэнтерологических проявлений при лечении больных новой коронавирусной инфекцией (COVID-19). Врач. 2022; 33 (1): 80-88. doi: 10.29296/25877305-2022-01-14.

244. Andreev D.N., Maev I.V., Bordin D.S. et al. Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials. Consilium Medicum. 2022;24(5):333-338. (in Russ.) doi: 10.26442/20751753.2022.5.201863.@@ Андреев Д.Н., Маев И.В., Бордин Д.С. и др. Эффективность включения ребамипида в схемы эрадикационной терапии инфекции Helicobacter pylori в России: метаанализ контролируемых исследований. Consilium Medicum. 2022;24(5):333-338. doi: 10.26442/20751753.2022.5.201863.

245. Uspensky Y.P., Baryshnikova N.V., Krasnov A.A., Petlenko S.V., Apryatina V.A. Topical issues of prevention of stomach cancer. Consilium medicum. 2022; 24(5): 357-364. (In Russ.) doi: 10.26442/20751753.2022.5.201922.@@ Успенский Ю.П., Барышникова Н.В., Краснов А.А., Петленко С.В., Апрятина В.А. Актуальные вопросы профилактики рака желудка. Consilium medicum. 2022; 24(5): 357-364. doi: 10.26442/20751753.2022.5. 201922.

246. Uspensky Yu. P., Baryshnikova N.V., Krasnov A.A., Petlenko S.V., Apryatina V.A. The effect of Regasthym Gastro on the restoration of acid production in the stomach according to daily pH-metry in patients with chronic atrophic gastritis. Experimental and clinical gastroenterology. 2022;198(2): 40-47. (in Russ.) doi: 10.31146/1682-8658-ecg-198-2-40-47.@@ Успенский Ю.П., Барышникова Н.В., Краснов А.А., Петленко С.В., Апрятина В.А. Влияние Регастим Гастро на восстановление кислотопродукции в желудке по данным суточной рН-метрии у больных хроническим атрофическим гастритом. Экспериментальная и клиническая гастроэнтерология. 2022;198(2): 40-47. doi: 10.31146/1682-8658-ecg-198-2-40-47.

247. Patel A.D., Prajapati N.K. Review on biochemical importance of vitamin-U. Journal of Chemical and Pharmaceutical Research. 2012, 4(1):209-215.

248. Kopinski J.S., Fogarty R., McVeigh J. Effect of s-methylmethionine sulphonium chloride on oesophagogastric ulcers in pigs. Aust Vet J. 2007 Sep;85(9):362-7. doi: 10.1111/j.1751-0813.2007.00197.x.

249. Ichikawa T, Ito Y, Saegusa Y, Iwai T, Goso Y, Ikezawa T, Ishihara K. Effects of combination treatment with famotidine and methylmethionine sulfonium chloride on the mucus barrier of rat gastric mucosa. J Gastroenterol Hepatol. 2009 Mar;24(3):488-92. doi: 10.1111/j.1440-1746.2008.05667.x.

250. Lee N.Y., Park K.Y., Min H.J., Song K.Y., Lim Y.Y., Park J., Kim B.J., Kim M.N. Inhibitory Effect of Vitamin U (S-Methylmethionine Sulfonium Chloride) on Differentiation in 3T3-L1 Pre-adipocyte Cell Lines. Ann Dermatol. 2012 Feb;24(1):39-44. doi: 10.5021/ad.2012.24.1.39.

251. Gezginci-Oktayoglu S., Turkyilmaz I.B., Ercin M., Yanardag R., Bolkent S. Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties. Protoplasma. 2016 Jan;253(1):127-35. doi: 10.1007/s00709-015-0796-3.

252. Ganu R.S., Ishida Y., Koutmos M., Kolokotronis S.O., Roca A.L., Garrow T.A., Schook L.B. Evolutionary Analyses and Natural Selection of Betaine-Homocysteine S-Methyltransferase (BHMT) and BHMT2 Genes. PLoS One. 2015 Jul 27;10(7): e0134084. doi: 10.1371/journal.pone.0134084.

253. Celik E., Tunali S., Gezginci-Oktayoglu S., Bolkent S., Can A., Yanardag R. Vitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis. Toxicol Mech Methods. 2021 Oct;31(8):600-608. doi: 10.1080/15376516.2021.1943089.

254. Ivashkin K.V., Izatullaev E.A., Korneeva V.R. Gastric Cytoprotection as Basis of Gastrointestinal Mucosa Protection and Repair in Erosive Ulcerative Lesions of Various Aetiologies. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(5):7-17. (In Russ.) doi: 10.22416/1382-4376-2020-30-7-17.@@ Ивашкин К.В., Изатуллаев Е.А., Корнеева В.Р. Желудочная цитопротекция как основа защиты и восстановления слизистой оболочки желудочно-кишечного тракта при эрозивно-язвенном поражении различной этиологии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(5):7-17. doi: 10.22416/1382-4376-2020-30-7-17.

255. Ichikawa T., Ito Y., Saegusa Y., Iwai T., Goso Y., Ikezawa T., Ishihara K. Effects of combination treatment with famotidine and methylmethionine sulfonium chloride on the mucus barrier of rat gastric mucosa. J Gastroenterol Hepatol. 2009 Mar;24(3):488-92. doi: 10.1111/j.1440-1746.2008.05667.x.

256. Drozdov V.N., Shih E.V., Astapovskij A.A., Pavlova L.I., Tormyshov I.A. Effect of 6-month S-methylmethionine intake on the quality of life and dyspepsia symptoms in patients with chronic gastritis. Voprosy pitaniia [Problems of Nutrition]. 2023; 92 (2): 80-6. (in Russ.) doi: 10.33029/0042-8833-2023-92-2-80-86.@@ Дроздов В.Н., Ших Е.В., Астаповский А.А., Павлова Л.И., Тормышов И.А., Пономаренко Т.М. Влияние 6-месячного приема S-метилметионина на качество жизни и симптомы диспепсии у пациентов с хроническим гастритом. Вопросы питания. 2023. Т. 92, № 2. С. 80-86. doi: 10.33029/0042-8833-2023-92-2-80-86.

257. Tryapyshko A.A., Dekhnich N.N. Combination of gastroprotectors and probiotics in the eradication of H. pylori infection: results of a randomized comparative clinical trial. Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(2):142-149.@@ Тряпышко А.А., Дехнич Н.Н. Комбинация гастропротекторов и пробиотиков в эрадикации инфекции H. pylori: результаты рандомизированного сравнительного клинического исследования. Клиническая микробиология и антимикробная химиотерапия. Том 25, № 2, 2023, с. 142-149.

258. Khlynov I.B., Khlynova R.I., Abduragimova L. Effectiveness and safety of vitamin U in patients with dyspepsia in real clinical practice. Vrach. 2023;34(11):30-33. (in Russ.) doi: 10.29296/25877305-2023-11-07.@@ Хлынов И.Б., Хлынова Р.И., Абдурагимова Л.З. Эффективность и безопасность витамина U у больных диспепсией в реальной клинической практике. Врач. 2023; (11): 30-33. doi: 10.29296/25877305-2023-11-07.

259. Khomeriki NM, Morozov IA. Peculiarities of cytoprotection in the stomach and some aspects of pharmacological action of bismuth drugs. Meditsinskiy sovet = Medical Council. 2017;(11):112-119. (In Russ.) doi: 10.21518/2079-701X-2017-11-112-119.@@ Хомерики НМ, Морозов ИА. Особенности цитопротекции в желудке и некоторые аспекты фармакологического действия препаратов висмута. Медицинский Совет. 2017;(11):112-119. doi: 10.21518/2079-701X-2017-11-112-119.

260. Abduragimova L., Khlynov I., Khlynova R. Autoimmune gastritis: clinical picture, diagnosis, treatment. Vrach (The Doctor). 2023; (12): 86-90. doi: 10.29296/25877305-2023-12-18.@@ Абдурагимова Л.З., Хлынов И.Б., Хлынова Р.И. и др. Аутоиммунный гастрит: клиника, диагностика, лечение. Врач. 2023; (12): 86-90. doi: 10.29296/25877305-2023-12-18.

261. Pilat T.L., Minushkin O.N., Lazebnik L.B., Zverkov I.V., Kuznetsova Y.G., Khanferyan R.A. Features of diet therapy for H. pylori associated diseases of the gastrointestinal tract. Meditsinskiy sovet = Medical Council. 2022;(15):46-61. (In Russ.) doi: 10.21518/2079-701X-2022-16-15-46-61.@@ Пилат Т.Л., Минушкин О.Н., Лазебник Л.Б., Зверков И.В., Кузнецова Ю.Г., Ханферьян Р.А. Особенности диетотерапии при H. pylori-ассоциированных заболеваниях желудочно-кишечного тракта. Медицинский Совет. 2022;(15):46-61. doi: 10.21518/2079-701X-2022-16-15-46-61..

262. Baker D.A. Plants against Helicobacter pylori to combat resistance: An ethnopharmacological review. Biotechnol Rep (Amst). 2020 May 21;26: e00470. doi: 10.1016/j.btre.2020.e00470.

263. Valieva Z.S. Efficacy of pharmacotherapy for postoperative pain in cardiac surgery. Economics and Society. 2023;2 (105):513-516. (in Russ.)@@ Вaлиевa З.С. Неэффективность антигеликобактерной терапии. Экономика и социум. - 2023. - № . 2 (105). -С.513-516.

264. Graham D.Y., El-Serag H.B. European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut. 2021 Jan;70(1):1-2. doi: 10.1136/gutjnl-2020-322385.

265. Nyssen O.P., Bordin D., Tepes B. et al.; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021 Jan;70(1):40-54. doi: 10.1136/gutjnl-2020-321372.

266. Bordin D.S. Errors in the diagnosis and treatment of Helicobacter pylori infection: in anticipation of new conciliation documents. Experimental and Clinical Gastroenterology. 2021;(9):5-14. (In Russ.) doi: 10.31146/1682-8658-ecg-193-9-5-14.@@ Бордин Д.С. Ошибки диагностики и лечения инфекции Helicobacter pylori: в преддверии новых согласительных документов. Экспериментальная и клиническая гастроэнтерология. 2021;(9):5-14. doi: 10.31146/1682-8658-ecg-193-9-5-14.

267. Lazebnik L.B. Patient compliance improvement as one of the conditions for reducing antibiotic resistance and increasing the effectiveness of anti-Helicobacter therapy. RMJ. Medical Review. 2018; 7(II):72-76. (in Russ.)@@ Лазебник Л.Б. Повышение комплаентности пациентов как одно из условий снижения антибиотикорезистентности и повышения эффективности антихеликобактерной терапии. РМЖ. Медицинское обозрение. 2018. № 7(II). С. 72-76.

268. Al-Eidan F.A., McElnay J.C., Scott M.G., McConnell J.B. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002 Feb;53(2):163-71. doi: 10.1046/j.0306-5251.2001.01531.x.

269. Shcherbakov P., Potapov A., Dublina E. Et al. Schemes for the eradication of helicobacter pylori strains resistant to metronidazole among children. Current Pediatrics. 2007;6(5):100-104. (in Russ.)@@ Щербаков П., Потапов А., Дублина Е. и др. Схемы эрадикации штаммов helicobacter pylori, резистентных к метронидазолу у детей. Вопросы современной педиатрии. 2007;6(5):100-104.

270. Graham D.Y., Lew G.M., Malaty H.M. et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493-6. doi: 10.1016/0016-5085(92)90095-g..

271. Wermeille J., Cunningham M., Dederding J.P. et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002 Mar;26(3):216-9. PMID: 11981460..

272. Boltin D., Ben-Zvi H., Perets T.T., Kamenetsky Z., Samra Z., Dickman R., Niv Y. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? J Clin Microbiol. 2015 Feb;53(2):522-7. doi: 10.1128/JCM.03001-14..

273. Minushkin O., Zverkov I., Volodin D., Ivanova O., Shuleshova A. Efficiency of the drug “Pilobact AM” in eradication therapy of duodenal ulcer. Doctor. 2008;5:67-9.@@ Минушкин О., Зверков И., Володин Д., Иванова О., Шулешова А. Эффективность препарата «Пилобакт AM» в эрадикационной терапии язвенной болезни двенадцатиперстной кишки. Врач. 2008;5:67-9.

274. Lazebnik L.B. Increasing the efficiency of eradication anti-Helicobacter therapy by combined pharmaceuticals set use. THERAPY. 2022;8(5):129-135. (in Russ.) doi: 10.18565/therapy.2022.5.129-135.@@ Лазебник Л.Б. Повышение эффективности эрадикационной антихеликобактерной терапии с использованием комбинированного набора фармпрепаратов. Терапия. 2022. - Т. 8. - № . 5. - С. 129-135. doi: 10.18565/therapy.2022.5.129-135..

275. Tringali A., Thomson M., Dumonceau J.M. et al. Pediatric gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Guideline Executive summary. Endoscopy. 2017 Jan;49(1):83-91. doi: 10.1055/s-0042-111002..

276. Hyams J.S., Di Lorenzo C., Saps M., Shulman R.J., Staiano A., van Tilburg M. Functional Disorders: Children and Adolescents. Gastroenterology. 2016 Feb 15: S0016-5085(16)00181-5. doi: 10.1053/j.gastro.2016.02.015..

277. Jones N.L., Koletzko S., Goodman K. et al.; ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. doi: 10.1097/MPG.0000000000001594..

278. Roma E., Miele E. Helicobacter pylori Infection in Pediatrics. Helicobacter. 2015 Sep;20 Suppl 1:47-53. doi: 10.1111/hel.12257..

279. Kornienko E.A. Helicobacter pylori infection in children. Moscow. GEOTAR-media, 2011, 272 p. (in Russ.)@@ Корниенко Е.А. Инфекция Helicobacter pylori у детей. - ГЭОТАР-медиа, М., 2011, 272 с.

280. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019 Apr;98(15): e15180. doi: 10.1097/MD.0000000000015180.

281. Zhu R., Chen K., Zheng Y.Y. et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014 Dec 21;20(47):18013-21. doi: 10.3748/wjg.v20.i47.18013..

282. McFarland L.V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016 Aug;4(4):546-61. doi: 10.1177/2050640615617358.

283. Feng J.R., Wang F., Qiu X., McFarland L.V., Chen P.F., Zhou R., Liu J., Zhao Q., Li J. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017 Oct;73(10):1199-1208. doi: 10.1007/s00228-017-2291-6..

284. Kornienko E.A., Parolova N.I. Microbiota of the stomach and the potential of probiotics in H. pylori eradication. Pharmateca. 2017; 13: 24-30. (in Russ.)@@ Корниенко Е.А., Паролова Н.И. Микробиота желудка и возможности пробиотиков в эрадикации H. pylori. Фарматека. 2017; 13: 24-30.

285. Cardaropoli S., Rolfo A., Todros T. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol. 2014 Jan 21;20(3):654-64. doi: 10.3748/wjg.v20.i3.654.

286. Burkov S.G., Bordin D.S., Sharapova E.I., Markina N.F. Influence of helicobacter pylori on clinical course of pregnancy. Experimental and Clinical Gastroenterology. 2017;(5):20-23. (In Russ.)@@ Бурков С.Г., Бордин Д.С., Шарапова Е.И., Маркина Н.Ф. Влияние helicobacter pylori на течение беременности. Экспериментальная и клиническая гастроэнтерология. 2017;(5):20-23..

287. Franceschi F., Di Simone N., D’Ippolito S. et al. Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia? Helicobacter. 2012 Dec;17(6):426-34. doi: 10.1111/j.1523-5378.2012.00966.x.

288. Karaer A., Ozkan O., Ozer S., Bayir B., Kilic S., Babur C., Danişman N. Gastrointestinal symptoms and Helicobacter pylori infection in early pregnancy. A seroepidemiologic study. Gynecol Obstet Invest. 2008;66(1):44-6. doi: 10.1159/000115845.

289. Sandven I., Abdelnoor M., Wethe M., Nesheim B.I., Vikanes A., Gjønnes H., Melby K.K. Helicobacter pylori infection and Hyperemesis gravidarum. An institution-based case-control study. Eur J Epidemiol. 2008;23(7):491-8. doi: 10.1007/s10654-008-9261-3.

290. Golberg D., Szilagyi A., Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol. 2007 Sep;110(3):695-703. doi: 10.1097/01.AOG.0000278571.93861.26.

291. Guven M.A., Ertas I.E., Coskun A., Ciragil P. Serologic and stool antigen assay of Helicobacter pylori infection in hyperemesis gravidarum: which test is useful during early pregnancy? Taiwan J Obstet Gynecol. 2011 Mar;50(1):37-41. doi: 10.1016/j.tjog.2009.11.003.

292. Frigo P., Lang C., Reisenberger K., Kölbl H., Hirschl A.M. Hyperemesis gravidarum associated with Helicobacter pylori seropositivity. Obstet Gynecol. 1998 Apr;91(4):615-7. doi: 10.1016/s0029-7844(97)00709-6.

293. Kazerooni T., Taallom M., Ghaderi A.A. Helicobacter pylori seropositivity in patients with hyperemesis gravidarum. Int J Gynaecol Obstet. 2002 Dec;79(3):217-20. doi: 10.1016/s0020-7292(02)00298-9.

294. Salimi-Khayati A., Sharami H., Mansour-Ghanaei F., Sadri S., Fallah M.S. Helicobacter pylori aeropositivity and the incidence of hyperemesis gravidarum. Med Sci Monit. 2003 Jan;9(1): CR12-5. PMID: 12552243.

295. Cevrioglu A.S., Altindis M., Yilmazer M., Fenkci I.V., Ellidokuz E., Kose S. Efficient and non-invasive method for investigating Helicobacter pylori in gravida with hyperemesis gravidarum: Helicobacter pylori stool antigen test. J Obstet Gynaecol Res. 2004 Apr;30(2):136-41. doi: 10.1111/j.1447-0756.2003.00173.x.

296. Koçak I., Akcan Y., Ustün C., Demirel C., Cengiz L., Yanik F.F. Helicobacter pylori seropositivity in patients with hyperemesis gravidarum. Int J Gynaecol Obstet. 1999 Sep;66(3):251-4. doi: 10.1016/s0020-7292(99)00091-0.

297. Bezircioğlu I., Elveren H.B., Baloğlu A., Biçer M. The positivity of Helicobacter pylori Stool Antigen in patients with Hyperemesis gravidarum. J Turk Ger Gynecol Assoc. 2011 Jun 1;12(2):71-4. doi: 10.5152/jtgga.2011.18.

298. Kazemzadeh M., Kashanian M., Baha B., Sheikhansari N. Evaluation of the relationship between Helicobacter Pylori infection and Hyperemesis Gravidarum. Med J Islam Repub Iran. 2014 Jul 21;28:72. PMID: 25405137.

299. Niemeijer M.N., Grooten I.J., Vos N. et al. Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis. Am J Obstet Gynecol. 2014 Aug;211(2):150.e1-15. doi: 10.1016/j.ajog.2014.02.012.

300. Muhsen K., Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter. 2008 Oct;13(5):323-40. doi: 10.1111/j.1523-5378.2008.00617.x.

301. Weyermann M., Rothenbacher D., Gayer L. et al. Role of Helicobacter pylori infection in iron deficiency during pregnancy. Am J Obstet Gynecol. 2005 Feb;192(2):548-53. doi: 10.1016/j.ajog.2004.08.028.

302. Mulayim B., Celik N.Y., Yanik F.F. Helicobacter pylori infection detected by 14C-urea breath test is associated with iron deficiency anemia in pregnant women. J Obstet Gynaecol Res. 2008 Dec;34(6):980-5. doi: 10.1111/j.1447-0756.2008.00822.x.

303. Malik R., Guleria K., Kaur I., Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011 Aug;134(2):224-31. PMID: 21911976.

304. Ponzetto A., Cardaropoli S., Piccoli E., Rolfo A., Gennero L., Kanduc D., Todros T. Pre-eclampsia is associated with Helicobacter pylori seropositivity in Italy. J Hypertens. 2006 Dec;24(12):2445-9. doi: 10.1097/HJH.0b013e3280109e8c.

305. Blecker U., Lanciers S., Keppens E., Vandenplas Y. Evolution of Helicobacter pylori positivity in infants born from positive mothers. J Pediatr Gastroenterol Nutr. 1994 Jul;19(1):87-90. doi: 10.1097/00005176-199407000-00014.

306. Bunn J.E., Thomas J.E., Harding M., Coward W.A., Weaver L.T. Placental acquisition of maternal specific IgG and Helicobacter pylori colonization in infancy. Helicobacter. 2003;8(5):568-72. doi: 10.1046/j.1523-5378.2003.00178.x.

307. Rothenbacher D., Bode G., Brenner H. History of breastfeeding and Helicobacter pylori infection in pre-school children: results of a population-based study from Germany. Int J Epidemiol. 2002 Jun;31(3):632-7. doi: 10.1093/ije/31.3.632.

308. Kitagawa M., Natori M., Katoh M., Sugimoto K., Omi H., Akiyama Y., Sago H. Maternal transmission of Helicobacter pylori in the perinatal period. J Obstet Gynaecol Res. 2001 Aug;27(4):225-30. doi: 10.1111/j.1447-0756.2001.tb01256.x.

309. Yang Y.J., Sheu B.S., Lee S.C., Yang H.B., Wu J.J. Children of Helicobacter pylori-infected dyspeptic mothers are predisposed to H. pylori acquisition with subsequent iron deficiency and growth retardation. Helicobacter. 2005 Jun;10(3):249-55. doi: 10.1111/j.1523-5378.2005.00317.x..

310. Burkov S.G., Polozhenkova L.A. [Diseases of the digestive system and pregnancy]. Handbook of gastroenterology / Edited by F.I. Komarov, A.L. Grebenev. Moscow: Medicine, 1996;3:720. (in Russ.)@@ Бурков С.Г., Положенкова Л.А. Болезни органов пищеварения и беременность/ Руководство по гастроэнтерологии / Под ред. Ф.И. Комарова, А.Л. Гребенева. М.: Медицина, 1996;3:720.

311. Dore M.P., Cuccu M., Pes G.M., Manca A., Graham D.Y. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med. 2014 Sep;9(6):649-54. doi: 10.1007/s11739-013-1013-z.

312. Holz C., Busjahn A., Mehling H., Arya S., Boettner M., Habibi H., Lang C. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins. 2015 Jun;7(2):91-100. doi: 10.1007/s12602-014-9181-3.

313. Eremina E. Yu. Heartburn in pregnant women: safe treatment. Doctor. 2016;(10):17-21. (in Russ.)@@ Еремина Е.Ю. Изжога у беременных: безопасное лечение. Врач. 2016. -№ 10. -С.17-21.

314. Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):849-77. doi: 10.1016/j.bpg.2007.06.002.

315. Kivi M., Johansson A.L., Reilly M., Tindberg Y. Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect. 2005 Aug;133(4):645-52. doi: 10.1017/s0950268805003900.

316. Kato M., Ota H., Okuda M. et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019 Aug;24(4): e12597. doi: 10.1111/hel.12597.

317. Rokkas T., Sechopoulos P., Pistiolas D., Margantinis G., Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1128-33. doi: 10.1097/MEG.0b013e3283398d37.

318. Livzan M.A. Underwater rocks of anti-helicobacter therapy. Therapeutic Archive. 2019; 91 (8): 141-147. (in Russ.) doi: 10.26442/00403660.2019.08.000386.@@ Ливзан М.А. Подводные камни антихеликобактерной терапии. Терапевтический архив. 2019; 91 (8): 141-147. doi: 10.26442/00403660.2019.08.000386.

319. Luzina E.V., Lazebnik L.B., Lareva N.V., Chartorizhskaya N.N., Dutova A.A., Melnikov V.V., Mutsolgova T.B. Experience of Chita the program of the Scientific Society of Gastroenterologists of Russia and Russian Scientific Medical Society of Internal Medicine “Physicians without helicobacteriosis”. Experimental and Clinical Gastroenterology. 2020;(3):34-46. (In Russ.) doi: 10.31146/1682-8658-ecg-175-3-34-46.@@ Лузина Е.В., Лазебник Л.Б., Ларева Н.В., Чарторижская Н.Н., Дутова А.А., Мельников В.В., Муцольгова Т.Б. Читинский опыт программы Научного Общества Гастроэнтерологов России и Российского Научного Медицинского Общества Терапевтов «Медики без хеликобактериоза». Экспериментальная и клиническая гастроэнтерология. 2020;(3):34-46. doi: 10.31146/1682-8658-ecg-175-3-34-46.

320. Dekhnich N.N., Kozlov R.S., Sablin O.A., Prischepova Ye.A. Helicobacter pylori infection diagnostics and choice of eradication treatment: results of inquiry of doctors from different regions of Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):33-41. (In Russ.) doi: 10.22416/1382-4376-2018-28-2-33-41.@@ Дехнич Н.Н., Козлов Р.С., Саблин О.А., Прищепова Е.А. Диагностика Helicobacter pylori и выбор эрадикационной терапии: результаты анкетирования врачей в различных регионах Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):33-41. doi: 10.22416/1382-4376-2018-28-2-33-41.

321. Peters C., Schablon A., Harling M., Wohlert C., Costa J.T., Nienhaus A. The occupational risk of Helicobacter pylori infection among gastroenterologists and their assistants. BMC Infect Dis. 2011 May 31;11:154. doi: 10.1186/1471-2334-11-154.

322. Kheyre H., Morais S., Ferro A., Costa A.R., Norton P., Lunet N., Peleteiro B. The occupational risk of Helicobacter pylori infection: a systematic review. Int Arch Occup Environ Health. 2018 Aug;91(6):657-674. doi: 10.1007/s00420-018-1315-6.

323. Kim H.Y., Kim N., Kim S.M., Seo J.H., Park E.H., Lee D.H. Seroprevalence of Helicobacter pylori Infection in Korean Health Personnel. Gut Liver. 2013 Nov;7(6):648-54. doi: 10.5009/gnl.2013.7.6.648.

324. Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol. 2014 Sep 28;20(36):12818-38. doi: 10.3748/wjg.v20.i36.12818.

325. Maev I.V., Bakulin I.G., Kurilovich S.A., Bakulina N.V., Andreev N.G., Golubev N.N. Helicobacter pylori and extragastroduodenal diseases: the proven facts and assumptions. Russian Journal of Evidence-Based Gastroenterology. 2018;7(3):45 59. (In Russ.) doi: 10.17116/dokgastro2018703145.@@ Маев И.В., Бакулин И.Г., Курилович С.А., Бакулина Н.В., Андреев Н.Г., Голубев Н.Н. Helicobacter pylori и экстрагастродуоденальные заболевания: доказанные факты и предположения. Доказательная гастроэнтерология. 2018;7(3):45 59. doi: 10.17116/dokgastro2018703145.

326. Kumar A., Sharma E., Marley A., Samaan M.A., Brookes M.J. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterol. 2022 Jan;9(1): e000759. doi: 10.1136/bmjgast-2021-000759.

327. Mulayamkuzhiyil Saju J., Mandal N., Kham N.I. et al. Is Helicobacter Pylori a Reason for Unexplained Iron Deficiency Anemia: A Systematic Review. Cureus. 2022 Sep 13;14(9): e29112. doi: 10.7759/cureus.29112.

328. Demerdash D.M.E., Ibrahim H., Hassan D.M., Moustafa H., Tawfik N.M. Helicobacter pylori associated to unexplained or refractory iron deficiency anemia: an Egyptian single-center experience. Hematol Transfus Cell Ther. 2018 Jul-Sep;40(3):219-225. doi: 10.1016/j.htct.2018.02.001.

329. Rodriguez-Castro K.I., Franceschi M., Noto A. et al. Clinical manifestations of chronic atrophic gastritis. Acta Biomed. 2018 Dec 17;89(8-S):88-92. doi: 10.23750/abm.v89i8-S.7921.

330. Kibru D, Gelaw B, Alemu A, Addis Z. Helicobacter pylori infection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia. BMC Infect Dis. 2014 Dec 9;14:656. doi: 10.1186/s12879-014-0656-3.

331. Asiimwe D., Bangi I., Esanyu J. et al. Association Between Helicobacter pylori Infection and Anemia Among Adult Dyspeptic Patients Attending Kiryandongo General Hospital, Uganda. J Blood Med. 2023 Jan 24;14:57-66. doi: 10.2147/JBM.S392146.

332. Hudak L., Jaraisy A., Haj S., Muhsen K. An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia. Helicobacter. 2017 Feb;22(1). doi: 10.1111/hel.12330.

333. Mayev I.V., Kochetov S.A. Clinical significance of Helicobacter pylori infection in iron-deficiency anemia: features of comprehensive treatment approach. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(1):29-36. (In Russ.) doi: 10.22416/1382-4376-2016-26-1-29-36.@@ Маев И.В., Кочетов С.А. Клиническое значение инфекцииHelicobacter pylori у пациентовс железодефицитной анемией: особенности комплексного подхода к терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(1):29-36. doi: 10.22416/1382-4376-2016-26-1-29-36.

334. Gheibi Sh., Farrokh-Eslamlou H.R., Noroozi M., Pakniyat A. Refractory iron deficiency anemia and Helicobacter Pylori Infection in pediatrics: A review. Iran J Ped Hematol Oncol. 2015;5(1):50-64.

335. Betesh A.L., Santa Ana C.A., Cole J.A., Fordtran J.S. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr. 2015 Jul;102(1):9-19. doi: 10.3945/ajcn.114.097394.

336. Gravina A.G., Zagari R.M., De Musis C., Romano L., Loguercio C., Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018 Aug 7;24(29):3204-3221. doi: 10.3748/wjg.v24.i29.3204.

337. Tsay F.W., Hsu P.I. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018 Aug 29;25(1):65. doi: 10.1186/s12929-018-0469-6.

338. Nakagawa S., Shimoyama T., Sato S., Chinda D., Nakaji S., Fukuda S., Schumacher U. Decreased iron stores in patients with Helicobacter pylori infection is improved by eradication without corresponding changes in the intake of iron and vitamin C. Cogent Medicine. 2018:5(1). doi: 10.1080/2331205X.2018.1432539.

339. José Augusto Urrego Díaz, W.O.R., Gómez M.A. Helicobacter pylori and hematologic diseases. Rev Col Gastroenterol. 2013;28 (4): 324-331.

340. Hutchinson C., Geissler C.A., Powell J.J., Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007 Sep;56(9):1291-5. doi: 10.1136/gut.2006.108613.

341. Yokota S., Konno M., Mino E., Sato K., Takahashi M., Fujii N. Enhanced Fe ion-uptake activity in Helicobacter pylori strains isolated from patients with iron-deficiency anemia. Clin Infect Dis. 2008 Feb 15;46(4): e31-3. doi: 10.1086/526784.

342. Senkovich O., Ceaser S., McGee D.J., Testerman T.L. Unique host iron utilization mechanisms of Helicobacter pylori revealed with iron-deficient chemically defined media. Infect Immun. 2010 May;78(5):1841-9. doi: 10.1128/IAI.01258-09.

343. Martino M.C., Stabler R.A., Zhang Z.W., Farthing M.J., Wren B.W., Dorrell N. Helicobacter pylori pore-forming cytolysin orthologue TlyA possesses in vitro hemolytic activity and has a role in colonization of the gastric mucosa. Infect Immun. 2001 Mar;69(3):1697-703. doi: 10.1128/IAI.69.3.1697-1703.2001..

344. Wang Z., Zhang L., Guo Z. et al. A unique feature of iron loss via close adhesion of Helicobacter pylori to host erythrocytes. PLoS One. 2012;7(11): e50314. doi: 10.1371/journal.pone.0050314.

345. van Vliet A.H., Stoof J., Vlasblom R. et al. The role of the Ferric Uptake Regulator (Fur) in regulation of Helicobacter pylori iron uptake. Helicobacter. 2002 Aug;7(4):237-44. doi: 10.1046/j.1523-5378.2002.00088.x.

346. Pich O.Q., Merrell D.S. The ferric uptake regulator of Helicobacter pylori: a critical player in the battle for iron and colonization of the stomach. Future Microbiol. 2013 Jun;8(6):725-38. doi: 10.2217/fmb.13.43.

347. Park S.A., Lee H.W., Hong M.H. et al. Comparative proteomic analysis of Helicobacter pylori strains associated with iron deficiency anemia. Proteomics. 2006 Feb;6(4):1319-28. doi: 10.1002/pmic.200500293.

348. Amedei A., Cappon A., Codolo G. et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006 Apr;116(4):1092-101. doi: 10.1172/JCI27177.

349. D’Elios M.M., Amedei A., Cappon A., Del Prete G., de Bernard M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol. 2007 Jul;50(2):157-64. doi: 10.1111/j.1574-695X.2007.00258.x.

350. Shan W., Kung H.F., Ge R. Comparison of Iron-Binding Ability Between Thr70-NapA and Ser70-NapA of Helicobacter pylori. Helicobacter. 2016 Jun;21(3):192-200. doi: 10.1111/hel.12266.

351. John S., Baltodano J.D., Mehta N., Mark K., Murthy U. Unexplained iron deficiency anemia: does Helicobacter pylori have a role to play? Gastroenterol Rep (Oxf). 2018 Aug;6(3):215-220. doi: 10.1093/gastro/goy001.

352. Capurso G., Lahner E., Marcheggiano A. et al. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection. Aliment Pharmacol Ther. 2001 Nov;15(11):1753-61. doi: 10.1046/j.1365-2036.2001.01101.x.

353. Flores S.E., Aitchison A., Day A.S., Keenan J.I. Helicobacter pylori infection perturbs iron homeostasis in gastric epithelial cells. PLoS One. 2017 Sep 5;12(9): e0184026. doi: 10.1371/journal.pone.0184026.

354. Boyanova L. Role of Helicobacter pylori virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011 Aug;6(8):843-6. doi: 10.2217/fmb.11.75.

355. Kato S., Osaki T., Kamiya S., Zhang X.S., Blaser M.J. Helicobacter pylori sabA gene is associated with iron deficiency anemia in childhood and adolescence. PLoS One. 2017 Aug 30;12(8): e0184046. doi: 10.1371/journal.pone.0184046.

356. Šterbenc A., Jarc E., Poljak M., Homan M. Helicobacter pylori virulence genes. World J Gastroenterol. 2019 Sep 7;25(33):4870-4884. doi: 10.3748/wjg.v25.i33.4870.

357. Öztekin M., Yılmaz B., Ağagündüz D., Capasso R. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases. 2021 Sep 23;9(4):66. doi: 10.3390/diseases9040066.

358. Kato S., Osaki T., Kamiya S., Zhang X.S., Blaser M.J. Helicobacter pylori sabA gene is associated with iron deficiency anemia in childhood and adolescence. PLoS One. 2017 Aug 30;12(8): e0184046. doi: 10.1371/journal.pone.0184046.

359. Novikov V.V., Lapin V.A., Melentiev D.A., Mokhonova E.V. Features of the human immune response to Helicobacrter pylori infectio. MediAl. 2019;(2):55-69. doi: 10.21145/2225-0026-2019-2-55-69.@@ Новиков В.В., Лапин В.А., Мелентьев Д.А., Мохонова Е.В. Особенности иммунного ответа человека на инфицирование Helicobacter pylori. МедиАль. 2019;(2):55-69. doi: 10.21145/2225-0026-2019-2-55-69.

360. Haile K., Yemane T., Tesfaye G., Wolde D., Timerga A., Haile A. Anemia and its association with Helicobacter pylori infection among adult dyspeptic patients attending Wachemo University Nigist Eleni Mohammad Memorial Referral Hospital, Southwest Ethiopia: A cross-sectional study. PLoS One. 2021 Jan 14;16(1): e0245168. doi: 10.1371/journal.pone.0245168.

361. Mendoza E., Duque X., Hernández Franco J.I. et al. Association between Active H. pylori Infection and Iron Deficiency Assessed by Serum Hepcidin Levels in School-Age Children. Nutrients. 2019 Sep 7;11(9):2141. doi: 10.3390/nu11092141.

362. Zhao Y., Zhao J., Ma H. et al. High Hepcidin Levels Promote Abnormal Iron Metabolism and Ferroptosis in Chronic Atrophic Gastritis. Biomedicines. 2023 Aug 22;11(9):2338. doi: 10.3390/biomedicines11092338.

363. Yuan W., Li Yumin, Yang Kehu, Ma Bin, Guan Quanlin, Wang D., Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010 Jun;45(6):665-76. doi: 10.3109/00365521003663670.

364. Huang X., Qu X., Yan W. et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J. 2010 May;86(1015):272-8. doi: 10.1136/pgmj.2009.089987.

365. Lahner E., Persechino S., Annibale B. Micronutrients (Other than iron) and Helicobacter pylori infection: a systematic review. Helicobacter. 2012 Feb;17(1):1-15. doi: 10.1111/j.1523-5378.2011.00892.x.

366. Franceschi F., Annalisa T., Teresa D.R. et al. Role of Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol. 2014 Sep 28;20(36):12809-17. doi: 10.3748/wjg.v20.i36.12809.

367. Prueksaritanond S, Barbaryan A, Mirrakhimov AE, Liana P, Ali AM, Gilman AD. A puzzle of hemolytic anemia, iron and vitamin B12 deficiencies in a 52-year-old male. Case Rep Hematol. 2013;2013:708489. doi: 10.1155/2013/708489.

368. Bergman M.P., Faller G., D’Elios M.M., et al. Gastric automminity. In: Mobley H.L.T., Mendz G.L., Hazell S.L., editors. Helicobacter pylori: Physiology and Genetics (chapter 36). Washington DC: ASM Press, 2001, pp. 429-40.

369. Lahner E., Marzinotto I., Lampasona V. et al. Autoantibodies Toward ATP4A and ATP4B Subunits of Gastric Proton Pump H+, K+-ATPase Are Reliable Serological Pre-endoscopic Markers of Corpus Atrophic Gastritis. Clin Transl Gastroenterol. 2020 Oct;11(10): e00240. doi: 10.14309/ctg.0000000000000240.

370. Rustgi S.D., Bijlani P., Shah S.C. Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therap Adv Gastroenterol. 2021 Aug 31;14:17562848211038771. doi: 10.1177/17562848211038771.

371. Youssefi M., Tafaghodi M., Farsiani H., Ghazvini K., Keikha M. Helicobacter pylori infection and autoimmune diseases; Is there an association with systemic lupus erythematosus, rheumatoid arthritis, autoimmune atrophy gastritis and autoimmune pancreatitis? A systematic review and meta-analysis study. J Microbiol Immunol Infect. 2021 Jun;54(3):359-369. doi: 10.1016/j.jmii.2020.08.011.

372. Mwafy S.N., Afana W.M. Hematological parameters, serum iron and vitamin B12 levels in hospitalized Palestinian adult patients infected with Helicobacter pylori: a case-control study. Hematol Transfus Cell Ther. 2018 Apr-Jun;40(2):160-165. doi: 10.1016/j.htct.2017.11.010.

373. O’Neill C.M., Weitz I.C., O’Connell C., Liebman H.A. Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center. Platelets. 2019;30(3):413-417. doi: 10.1080/09537104.2018.1453061.

374. Shah S.C., Iyer P.G., Moss S.F. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021 Apr;160(5):1831-1841. doi: 10.1053/j.gastro.2020.11.059.

375. Marino M.C., de Oliveira C.A., Rocha A.M. et al. Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut. 2007 Apr;56(4):469-74. doi: 10.1136/gut.2006.095125..

376. Bakulin I.G., Belousova L.N., Evdokimova L.S. Is thrombocytopenia always the problem of the hematologist? Diagnostic and therapeutic algorithms in practice of therapist and gastroenterologist. Farmareka. 2017; s5-17:78-84. (in Russ.)@@ Бакулин И.Г., Белоусова Л.Н., Евдокимова Л.С. Всегда ли тромбоцитопения - проблема гематолога? Лечебно-диагностические алгоритмы в практике терапевта и гастроэнтеролога. Фарматека. 2017; s5-17:78-84.

377. Idiopathic Thrombocytopenic Purpura (ITP) in Adults. Clinical Practice Guidelines. 2021. (in Russ.)@@ Идиопатическая тромбоцитопеническая пурпура (ИТП) у взрослых. Клинические рекомендации. 2021.

378. Zakharova N.V., Bakulin I.G., Simanenkov V.I., Maslygina A.A. Review of the maastricht V/florence consensus recommendations on the diagnosis and treatment of helicobacter pylori infection. Farmateka. 2016; S5 (16):8-26. (in Russ.)@@ Захарова Н.В., Бакулин И.Г., Симаненков В.И., Маслыгина А..А. Обзор рекомендаций пятого маастрихтского / флорентийского консенсуса по диагностике и лечению инфекции Нelicobacter pylori. Фарматека. - 2016. - № S5 (16). - С. 8-26.

379. Scandellari R., Allemand E., Vettore S., Plebani M., Randi M.L., Fabris F. Platelet response to Helicobacter pylori eradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies. Blood Coagul Fibrinolysis. 2009 Mar;20(2):108-13. doi: 10.1097/MBC.0b013e32832315d8.

380. Figura N., Franceschi F., Santucci A., Bernardini G., Gasbarrini G., Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2010 Sep;15 Suppl 1:60-8. doi: 10.1111/j.1523-5378.2010.00778.x.

381. Takahashi T., Yujiri T., Shinohara K. et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004 Jan;124(1):91-6. doi: 10.1046/j.1365-2141.2003.04735.x.

382. Bai Y., Wang Z., Bai X., Yu Z., Cao L., Zhang W., Ruan C. Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol. 2009 Mar;89(2):142-149. doi: 10.1007/s12185-008-0247-4.

383. Yamanishi S., Iizumi T., Watanabe E. et al. Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect Immun. 2006 Jan;74(1):248-56. doi: 10.1128/IAI.74.1.248-256.2006.

384. Pellicano R., Touscoz G.A., Smedile A., Berrutti M., Saracco G., Repici A., Ponzetto A., Rizzetto M. Prevalence of non-organ-specific autoantibodies in patients suffering from duodenal ulcer with and without Helicobacter pylori infection. Dig Dis Sci. 2004 Mar;49(3):395-8. doi: 10.1023/b: ddas.0000020491.78450.82.

385. Asahi A., Kuwana M., Suzuki H., Hibi T., Kawakami Y., Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica. 2006 Oct;91(10):1436-7. Epub 2006 Sep 7. PMID: 16963398.

386. Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol. 2014 Jan 21;20(3):714-23. doi: 10.3748/wjg.v20.i3.714.

387. Wu Z., Zhou J., Prsoon P., Wei X., Liu X., Peng B. Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals. Int J Hematol. 2012 Nov;96(5):588-93. doi: 10.1007/s12185-012-1187-6.

388. Veneri D., De Matteis G., Solero P. et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets. 2005 Aug;16(5):307-11. doi: 10.1080/09537100400028685.

389. Satoh T., Pandey J.P., Okazaki Y., Asahi A., Kawakami Y., Ikeda Y., Kuwana M. Single nucleotide polymorphism of interleukin-1beta associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens. 2009 Apr;73(4):353-7. doi: 10.1111/j.1399-0039.2009.01214.x.

390. Hashino S., Mori A., Suzuki S. et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol. 2003 Feb;77(2):188-91. doi: 10.1007/BF02983220.

391. Nomura S., Inami N., Kanazawa S. The effects of Helicobacter pylori eradication on chemokine production in patients with immune thrombocytopenic purpura. Eur J Haematol. 2004 Apr;72(4):304-5. doi: 10.1111/j.1600-0609.2004.00220.x.

392. Fujimura K., Kuwana M., Kurata Y. et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005 Feb;81(2):162-8. doi: 10.1532/ijh97.04146.

393. Franceschi F., Covino M., Roubaud Baudron C. Review: Helicobacter pylori and extragastric diseases. Helicobacter. 2019 Sep;24 Suppl 1: e12636. doi: 10.1111/hel.12636.

394. Ražuka-Ebela D., Giupponi B., Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2018 Sep;23 Suppl 1: e12520. doi: 10.1111/hel.12520.

395. Stasi R., Rossi Z., Stipa E., Amadori S., Newland A.C., Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. 2005 Apr;118(4):414-9. doi: 10.1016/j.amjmed.2004.09.014.

396. Kodama M., Kitadai Y., Ito M. et al. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter. 2007 Feb;12(1):36-42. doi: 10.1111/j.1523-5378.2007.00477.x.

397. Han B., Kim H.J., Yhim H.Y. et al. Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study. Ann Hematol. 2022 Jul;101(7):1435-1445. doi: 10.1007/s00277-022-04782-2.

398. Payandeh M., Raeisi D., Sohrabi N. et al. Poor platelet Count Response to Helicobacter Pylori Eradication in Patients with Severe Idiopathic Thrombocytopenic Purpura. Int J Hematol Oncol Stem Cell Res. 2013;7(3):9-14.

399. Ando K., Shimamoto T., Tauchi T. et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol. 2003 Apr;77(3):239-44. doi: 10.1007/BF02983780.

400. Sato R., Murakami K., Watanabe K. et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med. 2004 Sep 27;164(17):1904-7. doi: 10.1001/archinte.164.17.1904.

401. Suzuki T., Matsushima M., Shirakura K. et al. Association of inflammatory cytokine gene polymorphisms with platelet recovery in idiopathic thrombocytopenic purpura patients after the eradication of Helicobacter pylori. Digestion. 2008;77(2):73-8. doi: 10.1159/000121392.

402. Sato R., Murakami K., Okimoto T., Watanabe K., Kodama M., Fujioka T. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol. 2011 Aug;46(8):991-7. doi: 10.1007/s00535-011-0416-8.

403. Gan G.G., Norfaizal A.L., Bee P.C., Chin E.F., Habibah A.H., Goh K.L. Helicobacter pylori infection in chronic immune thrombocytopenic purpura patients in Malaysia. Med J Malaysia. 2013 Jun;68(3):231-3. PMID: 23749012.

404. Varma M., Yoe J. Importance of testing for Helicobacter pylori in patients with immune thrombocytopenia. Helicobacter. 2021 Dec;26(6): e12850. doi: 10.1111/hel.12850.

405. Yanushevich O. O. et al. [Comprehensive examination of patients with combined Helicobacter pathology of the gastrointestinal tract, periodontium and oral mucosa]. Medical and pharmaceutical journal “Pulse”. 2013;15(1-4):61-63. (in Russ.)@@ Янушевич О.О. и др. Комплексное обследование пациентов с сочетанной хеликобактерной патологией желудочно-кишечного тракта, пародонта и слизистой оболочки рта. Медико-фармацевтический журнал «Пульс». - 2013. - Т. 15. - № . 1-4. - С. 61-63.

406. Kurbonova N. I., Khabibova N.N. New possibilities of local antibacterial therapy and prevention of inflammatory periodontal diseases against the background of digestive system pathology. Biology and integrative medicine. 2020;3 (43):64-74. (in Russ.)@@ Курбонова Н.И., Хабибова Н.Н. Новые возможности местной антибактериальной терапии и профилактика воспалительных заболеваний пародонта на фоне патологии органов пищеварения. Биология и интегративная медицина. - 2020. - № . 3 (43). - С. 64-74.

407. Trukhan L.Y., Trukhan D.I. Stomatoligical problems of gastroenterological patients and their possible solutions. Meditsinskiy sovet = Medical Council. 2016;(19):134-137. (In Russ.) doi: 10.21518/2079-701X-2016-19-134-137.@@ Трухан Л.Ю., Трухан Д.И. Стоматологические проблемы гастроэнтерологических пациентов и возможные пути их решения. Медицинский Совет. 2016;(19):134-137. doi: 10.21518/2079-701X-2016-19-134-137.

408. Trukhan D.I., Trukhan L. Yu, Ivanova D.S. Comorbidity of diseases of the cardiovascular system and diseases of the digestive organs with changes in organs and tissue of the oral cavity. Clinical review for general practice. 2021; 3: 6-17. doi: 10.47407/kr2021.2.3.00044.@@ Трухан Д.И., Трухан Л.Ю., Иванова Д.С. Коморбидность заболеваний сердечно-сосудистой системы и болезней органов пищеварения с изменениями органов и тканей полости рта. Клинический разбор в общей медицине. 2021; 3: 6-17. doi: 10.47407/kr2021.2.3.00044.

409. Kovalevsky A. M. et al. Integrative approach to diagnostics and treatment of chronic generalized periodontitis and Helicobacter infection. Parodontologiya. 2012;17(4):85-88. (in Russ.)@@ Ковалевский А.М. и др. Интегративный подход в диагностике и лечении хронического генерализованного пародонтита и хеликобактерной инфекции. Пародонтология. 2012;17(4):85-88.

410. Sychev D. A. et al. Features of the dental and medical-social status of 2nd year students with Helicobacter infection in the oral cavity. (in Russ.)@@ Сычев Д.А. и др. Особенности стоматологического и медико-социального статуса студентов 2 курса с хеликобактерной инфекцией в полости рта]

411. Tsimpiris A., Tsolianos I., Grigoriadis A., Moschos I., Goulis D.G., Kouklakis G. Association of Chronic Periodontitis with Helicobacter pylori Infection in Stomach or Mouth: A Systematic Review and Meta-Analysis. Eur J Dent. 2023 May;17(2):270-282. doi: 10.1055/s-0042-1756690.

412. Moradi Y., Majidi L., Khateri S. et al. The association between periodontal diseases and helicobacter pylori: an updated meta-analysis of observational studies. BMC Oral Health. 2023 Jul 26;23(1):523. doi: 10.1186/s12903-023-03232-3.

413. Wei X., Zhao H.Q., Ma C., Zhang A.B., Feng H., Zhang D., Liu C. The association between chronic periodontitis and oral Helicobacter pylori: A meta-analysis. PLoS One. 2019 Dec 11;14(12): e0225247. doi: 10.1371/journal.pone.0225247.

414. Chen Z., Cai J., Chen Y.M., Wei J., Li H.B., Lu Y., Zhou Z., Chen X.L. A meta-analysis of the association between the presence of Helicobacter pylori and periodontal diseases. Medicine (Baltimore). 2019 May;98(22): e15922. doi: 10.1097/MD.0000000000015922.

415. Bouziane A., Ahid S., Abouqal R., Ennibi O. Effect of periodontal therapy on prevention of gastric Helicobacter pylori recurrence: a systematic review and meta-analysis. J Clin Periodontol. 2012 Dec;39(12):1166-73. doi: 10.1111/jcpe.12015.

416. Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J. 2021 Jun;71(3):188-196. doi: 10.1111/idj.12616.

417. Ren Q., Yan X., Zhou Y., Li W.X. Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection. Cochrane Database Syst Rev. 2016 Feb 7;2(2): CD009477. doi: 10.1002/14651858.CD009477.pub2.

418. Song H.Y., Li Y. Can eradication rate of gastric Helicobacter pylori be improved by killing oral Helicobacter pylori? World J Gastroenterol. 2013 Oct 21;19(39):6645-50. doi: 10.3748/wjg.v19.i39.6645.

419. Tongtawee T., Wattanawongdon W., Simawaranon T. Effects of periodontal therapy on eradication and recurrence of Helicobacter pylori infection after successful treatment. J Int Med Res. 2019 Feb;47(2):875-883. doi: 10.1177/0300060518816158.

420. Urrutia-Baca V.H., Paz-Michel B.A., Calderon-Porras A.N. et al. Oral Hygiene With Neutral Electrolyzed Water and Systemic Therapy Increases Gastric Helicobacter pylori Eradication and Reduces Recurrence. Clin Exp Dent Res. 2024 Aug;10(4): e927. doi: 10.1002/cre2.927.

421. Zaric S., Bojic B., Jankovic L.j., Dapcevic B., Popovic B., Cakic S., Milasin J. Periodontal therapy improves gastric Helicobacter pylori eradication. J Dent Res. 2009 Oct;88(10):946-50. doi: 10.1177/0022034509344559.

422. Konovalova Т.А., Kozlova M.V., Chorbinskaya S.A., Purveeva K.V. Clinical progression of parotid salivary gland sialadenosis based on the selected H. pylori eradication therapy. Parodontologiya. 2024;29(1):77-83. (In Russ.) doi: 10.33925/1683-3759-2024-892.@@ Коновалова Т.А., Козлова М.В., Чорбинская С.А., Пюрвеева К.В. Клиническое течение сиаладеноза околоушных слюнных желез в зависимости от выбора схемы эрадикационного лечения H. pylori-инфекции. Пародонтология. 2024;29(1):77-83. doi: 10.33925/1683-3759-2024-892.

423. Domracheva E. V., Sarsenbaeva A.S. Genetic features of Helicobacter pylori in patients with chronic pancreatitis with concomitant Helicobacter infection. Experimental and clinical gastroenterology. 2014;2 (102):59. (in Russ.)@@ Домрачева Е.В., Сарсенбаева А.С. Генетические особенности Helicobacter pylori у больных хроническим панкреатитом с сопутствующей хеликобактерной инфекцией. Экспериментальная и клиническая гастроэнтерология. - 2014. - № . 2 (102). - С. 59.

424. Domracheva E.V., Sarsenbaeva A.S. Clinical and functional features of patients with chronic pancreatitis and related helicobacter pylori-associated gastritis. Experimental and Clinical Gastroenterology. 2019;(3):31-37. (In Russ.)@@ Домрачева Е.В., Сарсенбаева А.С. Клинико-функциональные особенности больных хроническим панкреатитом с хроническим панкреатитом и сопутствующим helicobacter pylori-ассоциированным гастритом. Экспериментальная и клиническая гастроэнтерология. 2019;(3):31-37.

425. Gasbarrini A., Ojetti V., Pitocco D. et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol. 2000 Mar;35(3):260-3. doi: 10.1080/003655200750024119.

426. FedorchenkoYu.L., Koblova N.M., Obukhova G.G. Feature soft he course of chronic gastroduodenal ceresin diabetes mellitus and their treatment with kvamatel. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002;(2):82-88. (in Russ.)@@ Федорченко Ю.Л., Коблова Н.М., Обухова Г.Г. Особенности течения хронических гастродуоденальных язв при сахарном диабете и лечение их квамателом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002;(2):82-88.

427. Sargýn M., Uygur-Bayramicli O., Sargýn H., Orbay E., Yavuzer D., Yayla A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol. 2003 May;9(5):1126-8. doi: 10.3748/wjg.v9.i5.1126.

428. Fedorchenko Yu.L., Martynuk M.V., Zhmerenetsky K.W., Zharsky S.L., Davidovich I.M., Voronina N.V. Treatment regimen to an anti-helicobacter pyloril therapy in type II diabetic patients with chronic gastroduodenal disorders. Experimental and Clinical Gastroenterology. 2019;(6):22-28. (In Russ.) doi: 10.31146/1682-8658-ecg-166-6-22-28.@@ Федорченко Ю.Л., Мартынюк М.В., Жмеренецкий К.В., Жарский С.Л., Давидович И.М., Воронина Н.В. Схемы антихеликобактерной терапии больных хроническими гастродуоденальными заболеваниями и сахарным диабетом II типа. Экспериментальная и клиническая гастроэнтерология. 2019;(6):22-28. doi: 10.31146/1682-8658-ecg-166-6-22-28.

429. Maev I.V., Mkrtumyan A.M., Bektemirova L.G., Andreev D.N., Dicheva D.T. The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2):209-215. (in Russ.) doi: 10.26442/00403660.2022.2.201372.@@ Маев И.В., Мкртумян А.М., Бектемирова Л.Г., Андреев Д.Н., Дичева Д.Т. Эффективность эрадикационной терапии 1-й линии инфекции Helicobacter pylori у пациентов с сахарным диабетом 2-го типа. Терапевтический архив. 2022;94(2):209-215. doi: 10.26442/00403660.2022.02.201372.

430. Sviridova T.N., Ilchishina T.A., Kucheryavy Yu.A. The Role of a Gastroenterologist in Bariatric Surgery Planning: A Number of Important Aspects. Effective pharmacotherapy. 2022; 18 (22): 62-70. doi: 10.33978/2307-3586-2022-18-22-62-70.@@ Свиридова Т.Н., Ильчишина Т.А., Кучерявый Ю.А. Роль гастроэнтеролога при планировании бариатрического хирургического вмешательства: некоторые важные аспекты. Эффективная фармакотерапия. 2022; 18 (22): 62-70. (in Russ.) doi: 10.33978/2307-3586-2022-18-22-62-70.

431. Khasanov A.G. et al. On improving eradication therapy in patients who underwent palliative surgery for complicated forms of gastroduodenal ulcer disease. International Journal of Applied and Fundamental Research. 2015;12(5):846-849. (in Russ.)@@ Хасанов А.Г. и др. О совершенствовании эрадикационной терапии у больных перенесших паллиативные операции по поводу осложненных форм язвенной болезни гастродуоденальной зоны. Международный журнал прикладных и фундаментальных исследований. - 2015. - № . 12-5. - С. 846-849.

432. Chung W.C., Jeon E.J., Lee K.M. et al. Incidence and clinical features of endoscopic ulcers developing after gastrectomy. World J Gastroenterol. 2012 Jul 7;18(25):3260-6. doi: 10.3748/wjg.v18.i25.3260.

433. Giuliani A., Galati G., Demoro M., Scimò M., Pecorella I., Basso L. Screening of Helicobacter pylori infection after gastrectomy for cancer or peptic ulcer: results of a cohort study. Arch Surg. 2010 Oct;145(10):962-7. doi: 10.1001/archsurg.2010.211.

434. Bair M.J., Wu M.S., Chang W.H. et al. Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: correlates with operative procedures and duration after operation. J Formos Med Assoc. 2009 Jan;108(1):13-9. doi: 10.1016/S0929-6646(09)60027-9.

435. Park S., Chun H.J. Helicobacter pylori infection following partial gastrectomy for gastric cancer. World J Gastroenterol. 2014 Mar 21;20(11):2765-70. doi: 10.3748/wjg.v20.i11.2765.

436. Schilling D., Jakobs R., Peitz U., Sulliga M., Stolte M., Riemann J., Labenz J. Diagnostic accuracy of (13) C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcer disease: a prospective multicenter study. Digestion. 2001;63(1):8-13. doi: 10.1159/000051866.

437. Kim E.S., Park D.K., Hong S.H. et al. [Helicobacter pylori infection in the remnant stomach after radical subtotal gastrectomy]. Korean J Gastroenterol. 2003 Aug;42(2):108-14. Korean. PMID: 14532714.

438. Li X.B., Lu H., Chen H.M., Chen X.Y., Ge Z.Z. Role of bile reflux and Helicobacter pylori infection on inflammation of gastric remnant after distal gastrectomy. J Dig Dis. 2008 Nov;9(4):208-12. doi: 10.1111/j.1751-2980.2008.00348.x.

439. Li L., Zhou W., Li H., Yu C., Yan T., Yang N., Li Y.M. Antibiotic Resistance of Helicobacter pylori Isolated from Patients after Partial Gastrectomy: A Retrospective Study. Turk J Gastroenterol. 2021 Dec;32(12):996-1002. doi: 10.5152/tjg.2020.19354.

440. Fukuhara K., Osugi H., Takada N. et al. Correlation between duodenogastric reflux and remnant gastritis after distal gastrectomy. Hepatogastroenterology. 2004 Jul-Aug;51(58):1241-4. PMID: 15239287.

441. Abe H., Murakami K., Satoh S., Sato R., Kodama M., Arita T., Fujioka T. Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy. J Gastroenterol. 2005 Jun;40(6):563-9. doi: 10.1007/s00535-005-1589-9.

442. Kwon Y.H., Kim N., Lee J.Y. et al. The diagnostic validity of the (13) c-urea breath test in the gastrectomized patients: single tertiary center retrospective cohort study. J Cancer Prev. 2014 Dec;19(4):309-17. doi: 10.15430/JCP.2014.19.4.309.

443. Miyashita T., Miwa K., Inokuchi M. et al. Spontaneous clearance of Helicobacter pylori after pylorus-preserving gastrectomy for gastric cancer. Oncol Rep. 2013 Jul;30(1):299-303. doi: 10.3892/or.2013.2472.

444. Yoon K., Kim N., Kim J. et al. Dynamic Changes in Helicobacter pylori Status Following Gastric Cancer Surgery. Gut Liver. 2017 Mar 15;11(2):209-215. doi: 10.5009/gnl16224.

445. Adamopoulos A.B., Stergiou G.S., Sakizlis G.N., Tiniakos D.G., Nasothimiou E.G., Sioutis D.K., Achimastos A.D. Diagnostic value of rapid urease test and urea breath test for Helicobacter pylori detection in patients with Billroth II gastrectomy: a prospective controlled trial. Dig Liver Dis. 2009 Jan;41(1):4-8. doi: 10.1016/j.dld.2008.05.010.

446. Sheu B.S., Lee S.C., Lin P.W. et al. Carbon urea breath test is not as accurate as endoscopy to detect Helicobacter pylori after gastrectomy. Gastrointest Endosc. 2000 Jun;51(6):670-5. doi: 10.1067/mge.2000.105719.

447. Kwon Y.H., Kim N., Lee J.Y. et al. The diagnostic validity of the (13) c-urea breath test in the gastrectomized patients: single tertiary center retrospective cohort study. J Cancer Prev. 2014 Dec;19(4):309-17. doi: 10.15430/JCP.2014.19.4.309.

448. Chen Z., Liu H., Zhang Y., Jin T., Hu J., Yang K.13C -Urea Breath Test for the Diagnosis of H. pylori Infection in Patients after Partial Gastrectomy: A Systematic Review and Meta-Analysis. J Invest Surg. 2022 May;35(5):1125-1134. doi: 10.1080/08941939.2021.1972185.

449. Sheu B.S., Yang H.B., Wang Y.L., Kao A.W., Chuang C.H., Lin P.W., Chang Y.C. Stool antigen assay to screen H. pylori infection and to assess the success of 3-Day and 7-Day eradication therapy in the patients with partial gastrectomy. Helicobacter. 2002 Jun;7(3):199-204. doi: 10.1046/j.1523-5378.2002.00081.x.

450. Zhang F., Bao Z.J., Shi D.M. et al. Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy. Braz J Med Biol Res. 2016 Feb;49(2): e5080. doi: 10.1590/1414-431X20155080.

451. Robles-Campos R., Lujan-Mompean J.A., Parrilla-Paricio P. et al. Role of Helicobacter pylori infection and duodenogastric reflux in the pathogenesis of alkaline reflux gastritis after gastric operations. Surg Gynecol Obstet. 1993 Jun;176(6):594-8. PMID: 8322136.

452. Matsukura N., Tajiri T., Kato S. et al. Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Gastric Cancer. 2003;6(2):100-7. doi: 10.1007/s10120-003-0234-7.

453. Kubota K., Shimizu N., Nozaki K. et al. Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients. Dig Dis Sci. 2005 May;50(5):842-6. doi: 10.1007/s10620-005-2650-5.

454. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori; Liu W.Z., Xie Y., Cheng H. et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis. 2013 May;14(5):211-21. doi: 10.1111/1751-2980.12034.

455. Zhang F., Bao Z.J., Shi D.M., Xiang P., Xiao L., Huang Y.Q., Zhang G.S., Yin S.M. Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy. Braz J Med Biol Res. 2016 Feb;49(2): e5080. doi: 10.1590/1414-431X20155080.

456. Hwang J.J., Lee D.H., Yoon H., Shin C.M., Park Y.S., Kim N. Clinicopathological characteristics of patients who underwent additional gastrectomy after incomplete endoscopic resection for early gastric cancer. Medicine (Baltimore). 2017 Feb;96(7): e6172. doi: 10.1097/MD.0000000000006172.

457. Sinning C., Schaefer N., Standop J., Hirner A., Wolff M. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol. 2007 Mar;33(2):133-9. doi: 10.1016/j.ejso.2006.09.006.

458. Sakakibara M., Ando T., Ishiguro K. et al. Usefulness of Helicobacter pylori eradication for precancerous lesions of the gastric remnant. J Gastroenterol Hepatol. 2014 Dec;29 Suppl 4:60-4. doi: 10.1111/jgh.12772. Retraction in: J Gastroenterol Hepatol. 2018 Dec;33(12):2055. doi: 10.1111/jgh.14523.

459. Sitarz R., Maciejewski R., Polkowski W.P., Offerhaus G.J. Gastroenterostoma after Billroth antrectomy as a premalignant condition. World J Gastroenterol. 2012 Jul 7;18(25):3201-6. doi: 10.3748/wjg.v18.i25.3201.

460. Hamaguchi K., Ogawa K., Katsube T., Konno S., Aiba M. Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication. Langenbecks Arch Surg. 2004 Apr;389(2):83-91. doi: 10.1007/s00423-003-0451-x.

461. Cho S.J., Choi I.J., Kook M.C. et al. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther. 2013 Sep;38(5):477-89. doi: 10.1111/apt.12402.

462. Hutter M.M., Schirmer B.D., Jones D.B., Ko C.Y., Cohen M.E., Merkow R.P., Nguyen N.T. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2011 Sep;254(3):410-20; discussion 420-2. doi: 10.1097/SLA.0b013e31822c9dac.

463. Runkel N., Colombo-Benkmann M., Hüttl T.P., Tigges H., Mann O., Sauerland S. Bariatric surgery. Dtsch Arztebl Int. 2011 May;108(20):341-6. doi: 10.3238/arztebl.2011.0341.

464. Chung W.C., Jeon E.J., Lee K.M. et al. Clinical outcomes of the marginal ulcer bleeding after gastrectomy: as compared to the peptic ulcer bleeding with nonoperated stomach. Gastroenterol Res Pract. 2012;2012:624327. doi: 10.1155/2012/624327.

465. Lin Y.S., Chen M.J., Shih S.C., Bair M.J., Fang C.J., Wang H.Y. Management of Helicobacter pylori infection after gastric surgery. World J Gastroenterol. 2014 May 14;20(18):5274-82. doi: 10.3748/wjg.v20.i18.5274.

466. Sun K., Chen S., Ye J., Wu H., Peng J., He Y., Xu J. Endoscopic resection versus surgery for early gastric cancer: a systematic review and meta-analysis. Dig Endosc. 2016 Jul;28(5):513-25. doi: 10.1111/den.12596.

467. Lazebnik L.B., Tarasova L.V., Komarova E.A., Busalayeva E.I. Effect of Helicobacter pylori infection on the course of nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;(12):90-94. (In Russ.) doi: 10.31146/1682-8658-ecg-172-12-90-94.@@ Лазебник Л.Б., Тарасова Л.В., Комарова Е.А., Бусалаева Е.И. Влияние инфекции Helicobacter pylori на течение неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2019;(12):90-94. doi: 10.31146/1682-8658-ecg-172-12-90-94.

468. Khasanov O., Bektemirova Sh. Clinical and morphological parallelism of Helicobacter-associated gastroduodenal diseases against the background of fatty liver disease (NAFLD). EJMNS. 2022;2(11):58-62. (in Russ.)@@ Хасанов О., Бектемирова Ш. Клинико-морфологический параллелизм хеликобактер-ассоциированных гастродуоденальных заболеваний на фоне жировой болезни печени (НАЖБП). EJMNS. 2022;2(11):58-62.

469. Wei L., Ding H.G. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: What should we expect from a meta-analysis? Medicine (Baltimore). 2021 Aug 6;100(31): e26706. doi: 10.1097/MD.0000000000026706.

470. Ma Z., Chu X., Yan X., Wang W. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease for Asian and non-Asian population: A systematic review and meta-analysis. Front Public Health. 2022 Dec 8;10:1062942. doi: 10.3389/fpubh.2022.1062942.

471. Heydari K., Yousefi M., Alizadeh-Navaei R. et al. Helicobacter pylori Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Turk J Gastroenterol. 2022 Mar;33(3):171-181. doi: 10.5152/tjg.2022.21467.

472. Xu G., Ma S., Dong L. et al. Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Can J Gastroenterol Hepatol. 2023 Jan 25;2023:5521239. doi: 10.1155/2023/5521239.

473. Kang S.J., Kim H.J., Kim D., Ahmed A. Association between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United States. PLoS One. 2018 Aug 15;13(8): e0202325. doi: 10.1371/journal.pone.0202325.

474. Chen X., Peng R., Peng D., Xiao J., Liu D., Li R. An update: is there a relationship between H. pylori infection and nonalcoholic fatty liver disease? why is this subject of interest? Front Cell Infect Microbiol. 2023 Dec 8;13:1282956. doi: 10.3389/fcimb.2023.1282956.

475. Tomaszewska A., Gonciarz W., Rechcinski T., Chmiela M., Kurdowska A.K., Krupa A. Helicobacter pylori components increase the severity of metabolic syndrome and its hepatic manifestations induced by a high fat diet. Sci Rep. 2024 Mar 8;14(1):5764. doi: 10.1038/s41598-024-56308-7.

476. Xu G., Ma S., Dong L., Mendez-Sanchez N., Li H., Qi X. Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Can J Gastroenterol Hepatol. 2023 Jan 25;2023:5521239. doi: 10.1155/2023/5521239.

477. Chen C., Zhang C., Wang X., Zhang F., Zhang Z., Ma P., Feng S. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome. Eur J Gastroenterol Hepatol. 2020 Jul;32(7):857-866. doi: 10.1097/MEG.0000000000001601.

478. Gunji T., Matsuhashi N., Sato H. et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter. 2009 Oct;14(5):144-50. doi: 10.1111/j.1523-5378.2009.00705.x.

479. Chen L.W., Chien C.Y., Yang K.J., Kuo S.F., Chen C.H., Chien R.N. Helicobacter pylori Infection Increases Insulin Resistance and Metabolic Syndrome in Residents Younger than 50 Years Old: A Community-Based Study. PLoS One. 2015 May 28;10(5): e0128671. doi: 10.1371/journal.pone.0128671.

480. Dogan Z., Sarikaya M., Ergul B., Filik L. The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):242-5. doi: 10.5507/bp.2014.036.

481. Azami M., Baradaran H.R., Dehghanbanadaki H. et al. Association of Helicobacter pylori infection with the risk of metabolic syndrome and insulin resistance: an updated systematic review and meta-analysis. Diabetol Metab Syndr. 2021 Dec 18;13(1):145. doi: 10.1186/s13098-021-00765-x.

482. Polyzos S.A., Kountouras J., Zavos C., Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011 Apr;16(2):79-88. doi: 10.1111/j.1523-5378.2011.00822.x.

483. Tilg H., Moschen A.R., Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016 Sep;64(3):955-65. doi: 10.1002/hep.28456.

484. Niemelä S., Karttunen T., Korhonen T., Läärä E., Karttunen R., Ikäheimo M., Kesäniemi Y.A. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 1996 Jun;75(6):573-5. doi: 10.1136/hrt.75.6.573.

485. Roubaud Baudron C., Franceschi F., Salles N., Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2013 Sep;18 Suppl 1:44-51. doi: 10.1111/hel.12077.

486. Al-Fawaeir S., Zaid M.A., Awad A.A., Alabedallat B. Serum lipid profile in Helicobacter pylori infected patients. Am J Physiol Biochem Pharmacol. 2013;2(2), 1-4.

487. Sun Y., Fu D., Wang Y.K., Liu M., Liu X.D. Prevalence of Helicobacter pylori infection and its association with lipid profiles. Bratisl Lek Listy. 2016;117(9):521-524. doi: 10.4149/bll_2016_103.

488. Yang Y.J., Sheu B.S. Metabolic Interaction of Helicobacter pylori Infection and Gut Microbiota. Microorganisms. 2016 Feb 16;4(1):15. doi: 10.3390/microorganisms4010015.

489. Seo K.I., Heo J.J., Kim S.E. et al. Sex differences between Helicobacter pylori infection and cholesterol levels in an adult health checkup program. Helicobacter. 2020 Aug;25(4): e12704. doi: 10.1111/hel.12704.

490. Hashim M., Mohammed O., G/Egzeabeher T., Wolde M. The association of Helicobacter Pylori infection with dyslipidaemia and other atherogenic factors in dyspeptic patients at St. Paul’s Hospital Millennium Medical College. Heliyon. 2022 May 14;8(5): e09430. doi: 10.1016/j.heliyon.2022.e09430.

491. Nigatie M., Melak T., Asmelash D., Worede A. Dyslipidemia and Its Associated Factors Among Helicobacter pylori-Infected Patients Attending at University of Gondar Comprehensive Specialized Hospital, Gondar, North-West Ethiopia: A Comparative Cross-Sectional Study. J Multidiscip Healthc. 2022 Jul 15;15:1481-1491. doi: 10.2147/JMDH.S368832.

492. Jia E.Z., Zhao F.J., Hao B. et al. Helicobacter pylori infection is associated with decreased serum levels of high density lipoprotein, but not with the severity of coronary atherosclerosis. Lipids Health Dis. 2009 Dec 23;8:59. doi: 10.1186/1476-511X-8-59.

493. Kucukazman M., Yavuz B., Sacikara M. et al. The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci. 2009 Mar;54(3):604-7. doi: 10.1007/s10620-008-0391-y.

494. Cui Y., Wang Q., Chang R., Zhou X., Xu C. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. J Agric Food Chem. 2019 Mar 13;67(10):2754-2762. doi: 10.1021/acs.jafc.9b00080.

495. Gupta B., Rai R., Oertel M., Raeman R. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. Semin Liver Dis. 2022 May;42(2):122-137. doi: 10.1055/s-0042-1748037.

496. Martin-Nuñez G.M., Cornejo-Pareja I., Clemente-Postigo M., Tinahones F.J. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne). 2021 Jun 17;12:639856. doi: 10.3389/fendo.2021.639856.

497. Frost F., Kacprowski T., Rühlemann M. et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep. 2019 Dec 27;9(1):20100. doi: 10.1038/s41598-019-56631-4.

498. Aron-Wisnewsky J., Vigliotti C., Witjes J., Le P., Holleboom A.G., Verheij J., Nieuwdorp M., Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297. doi: 10.1038/s41575-020-0269-9.

499. Ji Won Kim, Tae Jun Kim, Ji Eun Kim et al. Impact of Helicobacter pylori Eradication on the Risk of Incident Nonalcoholic Fatty Liver Disease: A Cohort Study. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2022;22(2):131-138. doi: 10.7704/kjhugr.2021.0060.

500. Jamali R., Mofid A., Vahedi H., Farzaneh R., Dowlatshahi S. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013 Dec 6;13(12): e14679. doi: 10.5812/hepatmon.14679..

501. Polyzos S.A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., Kountouras J. Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study. Arq Gastroenterol. 2014 Jul-Sep;51(3):261-8. doi: 10.1590/s0004-28032014000300017.

502. Yu Y.Y., Tong Y.L., Wu L.Y., Yu X.Y. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep. 2022 Nov 14;12(1):19530. doi: 10.1038/s41598-022-23746-0.

503. Han Y.M., Lee J., Choi J.M. et al. The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors. PLoS One. 2021 Dec 13;16(12): e0260994. doi: 10.1371/journal.pone.0260994.

504. Maharshi V., Gupta P., Kumar V.L. et al. Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized-controlled pilot study. Gastroenterol Rep (Oxf). 2019 Nov 25;8(2):104-110. doi: 10.1093/gastro/goz058.

505. Pakhomova I.G., Malko-Skroz M.V. Differentiated approach to the choice of PPI in a patient with GERD in the practice of an outpatient (with a clinical case). Meditsinskiy sovet = Medical Council. 2020;(15):20-26. (In Russ.) doi: 10.21518/2079-701X-2020-15-20-26.@@ Пахомова И.Г., Малко-Скрозь М.В. Сочетанное течение ГЭРБ и функциональной диспепсии. Терапевтические возможности на клиническом примере. Медицинский Совет. 2020;(15):20-26. doi: 10.21518/2079-701X-2020-15-20-26.

506. Simanenkov V.I., Alekseenko S.A. Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra. Terapevticheskii arkhiv. 2022;94(8):935-939. (in Russ.) doi: 10.26442/00403660.2022.08.201787.@@ Симаненков В.И., Алексеенко С.А. Перспективы индивидуализированной эрадикационной терапии Helicobacter pylori. Pro et contra. Терапевтический архив. 2022;94(8):935-939. doi: 10.26442/00403660.2022.08.201787.

507. Sarsenbaeva A.S. Helicobacter pylori-associated comorbidity. Experimental and Clinical Gastroenterology. 2021;(9):38-52. (In Russ.) doi: 10.31146/1682-8658-ecg-193-9-38-52.@@ Сарсенбаева А.С. Helicobacter pylori-ассоциированная коморбидность. Экспериментальная и клиническая гастроэнтерология. 2021;(9):38-52. doi: 10.31146/1682-8658-ecg-193-9-38-52.

508. Khlynova R.I., Khromtsova O.M., Berdnikov R.B., Khlynov I.B. Helicobacter pylori infection reduces the risk of gastroesophageal reflux disease. Experimental and Clinical Gastroenterology. 2021;(9):96-101. (In Russ.) doi: 10.31146/1682-8658-ecg-193-9-96-101.@@ Хлынова Р.И., Хромцова О.М., Бердников Р.Б., Хлынов И.Б. Инфицированность Helicobacter pylori снижает риск развития гастроэзофагорефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2021;(9):96-101. doi: 10.31146/1682-8658-ecg-193-9-96-101.

509. Baryshnikova N.V., Zamyatina Yu.Е., Nevskaya Ye.V. Helicobacter pylori infection and esophageal pathology. University therapeutic journal (St. Petersburg). 2023;5(4):82-93. (in Russ.) doi: 10.56871/UTJ.2023.15.23.007.@@ Барышникова Н.В., Замятина Ю.Е., Невская Е.В. Инфекция Helicobacter pylori и патология пищевода. Университетский терапевтический вестник. 2023;5(4):82-93. doi: 10.56871/UTJ.2023.15.23.007.

510. Zhilina A.A., Lareva N.V., Luzina E.V. The role of interleukin 1β and interleukin 1 receptor antagonist polymorphism genes, Helicobacter pylori infection and the state of the gastric mucosa in the development and progression of gastroesophageal reflux disease. Pacific Medical Journal. 2020;(4):44-48. (In Russ.) doi: 10.34215/1609-1175-2020-4-44-48.@@ Жилина А.А., Ларева Н.В., Лузина Е.В. Роль полиморфизма генов интерлейкина-1β и антагониста рецептора интерлейкина-1, инфекции Helicobacter pylori и состояния слизистой оболочки желудка в развитии и прогрессировании гастроэзофагеальной рефлюксной болезни. Тихоокеанский медицинский журнал. 2020;(4):44-48. doi: 10.34215/1609-1175-2020-4-44-48.

511. Yarmolik E.S. Role of Helicobacter pylori infection in the development of chronic skin diseases. Journal of the Grodno State Medical University. 2012;4 (40):18-22. (in Russ.)@@ Ярмолик Е.С. Роль хеликобактерной инфекции в развитии хронических кожных заболеваний. Журнал Гродненского государственного медицинского университета. 2012;4 (40):18-22.

512. Abdurakhmanov M.M. et al. [The role of Helicobacter infection in the development of functional dyspepsia and acne vulgaris]. Likars’ ka sprava. 2022;(1-2):45-53. (in Russ.)

513. Abramyan M.V., Yakovleva A.V. The role of Helicobacter pylori in the pathogenesis of rosacea. Word science: problems and innovations. Penza. 2020, pp. 264-266. (in Russ.)]

514. Sebekina O.V., Trubitsyna I.E., Masharova A.A., D’iakova E.N. [Clinical variants of chronic urticaria associated with Helicobacter pylori]. Eksp Klin Gastroenterol. 2011;(5):20-5. (in Russ.) PMID: 21916230.

515. Morozova O.A. The role of Helicobacter infection in the development of chronic urticaria. Bulletin of the Ural Medical Academic Science. 2011;2-1:178-179. (in Russ.)@@ Морозова О.А. Роль хеликобактерной инфекции в развитии хронической крапивницы. Вестник Уральской медицинской академической науки. 2011;2-1:178-179.

516. Pavlenok N. V., Makhnovets E.N. Peculiarities of the clinical picture of vulgar psoriasis against the background of chronic Helicobacter infection. Bulletin of New Medical Technologies. 2007;14(3):106. (in Russ.)@@ Павленок Н.В., Махновец Е.Н. Особенности клинической картины вульгарного псориаза на фоне хронической хеликобактерной инфекции. Вестник новых медицинских технологий. 2007;14(3):106.

517. Karlova V.V. Eradication of Helicobacter pylori as a pathogenetically substantiated method in the therapy of rosacea. Medical Bulletin of the North Caucasus. 2008; 9 (1): 23-25.@@ Карлова В.В. Эрадикация Helicobacter pylori как патогенетически обоснованный метод в терапии розацеа. Медицинский вестник Северного Кавказа. 2008;9(1):23-25.

518. Karlova V. V. et al. Pilobact in the therapy of patients with rosacea. Siberian Journal of Dermatology and Venereology. 2005; (6): 33-34.@@ Карлова В.В. и др. Пилобакт в терапии больных розацеа. Сибирский журнал дерматологии и венерологии. 2005;(6):33-34.

519. Campuzano-Maya G. Cure of alopecia areata after eradication of Helicobacter pylori: a new association? World J Gastroenterol. 2011 Jul 14;17(26):3165-70. doi: 10.3748/wjg.v17.i26.3165.

520. Lazebnik L.B. et al. Skin itching as a possible manifestation of Helicobacter pylori infection. Experimental and clinical gastroenterology. 2012;(11):119-123. (in Russ.)@@ Лазебник Л.Б. и др. Кожный зуд как возможное проявление хеликобактериоза. Экспериментальная и клиническая гастроэнтерология. 2012;(11):119-123.

521. Guarneri C., Ceccarelli M., Rinaldi L., Cacopardo B., Nunnari G., Guarneri F. Helicobacter pylori and skin disorders: a comprehensive review of the available literature. Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12267-12287. doi: 10.26355/eurrev_202012_24019.

522. Taghavi Zenouz A., Mehdipour M., Jafari Heydarlou M., Gholizadeh N. Relationship between Lichen Planus and Helicobacter pylori Infection. J Dent Res Dent Clin Dent Prospects. 2010 Winter;4(1):17-20. doi: 10.5681/joddd.2010.005.,

523. Jørgensen A.R., Egeberg A., Gideonsson R., Weinstock L.B., Thyssen E.P., Thyssen J.P. Rosacea is associated with Helicobacter pylori: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):2010-2015. doi: 10.1111/jdv.14352.

524. Wang F.Y., Chi C.C. Rosacea, Germs, and Bowels: A Review on Gastrointestinal Comorbidities and Gut-Skin Axis of Rosacea. Adv Ther. 2021 Mar;38(3):1415-1424. doi: 10.1007/s12325-021-01624-x.,

525. Xue Q., Li X., Li Y., Xu J., Wu Z., Wang J. Dialogue between gastrointestinal tract and skin: New insights into the Helicobacter pylori and atopic dermatitis. Helicobacter. 2021 Apr;26(2): e12771. doi: 10.1111/hel.12771.

526. Azizzadeh M., Nejad Z.V., Ghorbani R., Pahlevan D. Relationship between Helicobacter pylori infection and psoriasis. Ann Saudi Med. 2014 May-Jun;34(3):241-4. doi: 10.5144/0256-4947.2014.241.

527. Yong W.C., Upala S., Sanguankeo A. Association between Psoriasis and Helicobacter pylori Infection: A Systematic Review and Meta-analysis. Indian J Dermatol. 2018 May-Jun;63(3):193-200. doi: 10.4103/ijd.IJD_531_17.

528. Abdel-Hamid S., Abdel-Monem S.A. Helicobacter pylori infection in psoriatic patients and its relation to psoriasis severity: Cross Sectional Study. Skin Res Technol. 2024 Aug;30(8): e70005. doi: 10.1111/srt.70005.

529. Yu M., Zhang R., Ni P., Chen S., Duan G. Helicobacter pylori Infection and Psoriasis: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2019 Sep 26;55(10):645. doi: 10.3390/medicina55100645.,

530. Doğan Z., Özdemir P., Ekşioğlu M., Filik L. Relationship between Helicobacter pylori infection and vitiligo: a prospective study. Am J Clin Dermatol. 2014 Oct;15(5):457-62. doi: 10.1007/s40257-014-0087-3.

531. Dua J., Elliot E., Bright P. et al. Pyoderma gangrenosum-like ulcer caused by Helicobacter cinaedi in a patient with x-linked agammaglobulinaemia. Clin Exp Dermatol. 2012 Aug;37(6):642-5. doi: 10.1111/j.1365-2230.2011.04293.x.

532. Murray P.R., Jain A., Uzel G. et al. Pyoderma gangrenosum-like ulcer in a patient with X-linked agammaglobulinemia: identification of Helicobacter bilis by mass spectrometry analysis. Arch Dermatol. 2010 May;146(5):523-6. doi: 10.1001/archdermatol.2010.86.

533. Turvey S.E., Leo S.H., Boos A. et al. Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia. J Clin Immunol. 2012 Dec;32(6):1404-8. doi: 10.1007/s10875-012-9750-8.

534. Swarnkar B., Anand G.R., Khandpur S., Kumar Panda A., Sharma M. Helicobacter-induced pyoderma gangrenosum-like skin ulcers in a case of Bruton’s agammaglobulinemia. Indian J Dermatol Venereol Leprol. 2023 Jul 19:1-3. doi: 10.25259/IJDVL_794_2022.

535. Luzina E. V., Lareva N.V., Lazebnik L.B., Dutova A.A., Chartorizhskaya N.N., Mutsolgova T.B. Helicobacter pylori and herpes viruses coinfection in chronic gastritis. Experimental and Clinical Gastroenterology. 2023;220(12): 27-35. (In Russ.) doi: 10.31146/1682-8658-ecg-220-12-27-35.@@ Лузина Е.В., Ларева Н.В., Лазебник Л.Б., Дутова А.А., Чарторижская Н.Н., Муцольгова Т.Б. Коинфекция Helicobacter pylori и герпесвирусами при хроническом гастрите. Экспериментальная и клиническая гастроэнтерология. 2023;220(12): 27-35. doi: 10.3114 6/1682-8658-ecg-220-12-27-35.

536. Balamtekin N., Artuk C., Arslan M., Gülşen M. The Effect of Helicobacter pylori on the Presentation and Clinical Course of Coronavirus Disease 2019 Infection. J Pediatr Gastroenterol Nutr. 2021 Apr 1;72(4):511-513. doi: 10.1097/MPG.0000000000003005.

537. Zhang M., Feng C., Zhang X., Hu S., Zhang Y., Min M., Liu B., Ying X., Liu Y. Susceptibility Factors of Stomach for SARS-CoV-2 and Treatment Implication of Mucosal Protective Agent in COVID-19. Front Med (Lausanne). 2021 Jan 14;7:597967. doi: 10.3389/fmed.2020.597967.

538. Price E. Could the severity of COVID-19 be increased by low gastric acidity? Crit Care. 2020 Jul 22;24(1):456. doi: 10.1186/s13054-020-03182-0.

539. Uno Y. Why Does SARS-CoV-2 Invade the Gastrointestinal Epithelium? Gastroenterology. 2020 Oct;159(4):1622-1623. doi: 10.1053/j.gastro.2020.04.006.

540. Sugimoto M., Yamaoka Y., Shirai N., Furuta T. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol. 2012 Mar;27(3):442-51. doi: 10.1111/j.1440-1746.2011.06964.x.

541. Hunt E.B., Sullivan A., Galvin J., MacSharry J., Murphy D.M. Gastric Aspiration and Its Role in Airway Inflammation. Open Respir Med J. 2018 Dec 26;12:83. doi: 10.2174/1874306401812010083.

542. Mitz H.S., Farber S.S. Demonstration of Helicobacter pylori in tracheal secretions. J Am Osteopath Assoc. 1993 Jan;93(1):87-91. PMID: 8423130.

543. Nakashima S., Kakugawa T., Yura H. et al. Identification of Helicobacter pylori VacA in human lung and its effects on lung cells. Biochem Biophys Res Commun. 2015 May 8;460(3):721-726. doi: 10.1016/j.bbrc.2015.03.096.

544. Ilvan A., Ozturkeri H., Capraz F., Cermik H., Kunter E. Investigation of Helicobacter pylori in bronchoscopic lung specimens of young male patients with bronchiectasis but without gastrointestinal symptoms. Clin Microbiol Infect. 2004 Mar;10(3):257-60. doi: 10.1111/j.1198-743x.2004.00868.x.

545. Dadashi A., Hosseinzadeh N. High seroprevalence of anti-Helicobacter pylori antibodies in patients with ventilator-associated pneumonia. J Res Med Sci. 2018 Sep 24;23:79. doi: 10.4103/jrms.JRMS_117_18.

546. Franceschi F., Tortora A., Gasbarrini G., Gasbarrini A. Helicobacter pylori and extragastric diseases. Helicobacter. 2014 Sep;19 Suppl 1:52-8. doi: 10.1111/hel.12159.

547. Arismendi Sosa A.C., Salinas Ibáñez A.G., Pérez Chaca M.V., Penissi A.B., Gómez N.N., Vega A.E. Inflammatory response induced by Helicobacter pylori infection in lung. Microb Pathog. 2020 Feb 26;142:104103. doi: 10.1016/j.micpath.2020.104103.

548. Xia X., Zhang L., Chi J. et al. Helicobacter pylori Infection Impairs Endothelial Function Through an Exosome-Mediated Mechanism. J Am Heart Assoc. 2020 Mar 17;9(6): e014120. doi: 10.1161/JAHA.119.014120.

549. Tobin N.P., Henehan G.T., Murphy R.P. et al. Helicobacter pylori-induced inhibition of vascular endothelial cell functions: a role for VacA-dependent nitric oxide reduction. Am J Physiol Heart Circ Physiol. 2008 Oct;295(4): H1403-13. doi: 10.1152/ajpheart.00240.2008.

550. Rasmi Y., Rouhrazi H., Khayati-Shal E., Shirpoor A., Saboory E. Association of endothelial dysfunction and cytotoxin-associated gene A-positive Helicobacter pylori in patients with cardiac syndrome X. Biomed J. 2016 Oct;39(5):339-345. doi: 10.1016/j.bj.2016.01.010.

551. Vijayvergiya R., Vadivelu R. Role of Helicobacter pylori infection in pathogenesis of atherosclerosis. World J Cardiol. 2015 Mar 26;7(3):134-43. doi: 10.4330/wjc.v7.i3.134.

552. Aydemir S., Eren H., Tekin I.O., Harmandar F.A., Demircan N., Cabuk M. Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm. 2010;2010:685903. doi: 10.1155/2010/685903.

553. Lai C.C., Ko W.C., Lee P.I., Jean S.S., Hsueh P.R. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020 Aug;56(2):106024. doi: 10.1016/j.ijantimicag.2020.106024.

554. Li G.F., An X.X., Yu Y. et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2021 Sep;70(9):1806-1808. doi: 10.1136/gutjnl-2020-323366.

555. Daniell HW. Acid suppressing therapy as a risk factor for Candida esophagitis. Dis Esophagus. 2016 Jul;29(5):479-83. doi: 10.1111/dote.12354.

556. Vaezi M.F., Yang Y.X., Howden C.W. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017 Jul;153(1):35-48. doi: 10.1053/j.gastro.2017.04.047.

557. Pappas P.G., Kauffman C.A., Andes D.R. et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):409-17. doi: 10.1093/cid/civ1194.

558. Lortholary O., Petrikkos G., Akova M. et al.; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:68-77. doi: 10.1111/1469-0691.12042.

559. Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4): e1-50. doi: 10.1093/cid/civ933.

560. Biagi F., Balduzzi D., Delvino P., Schiepatti A., Klersy C., Corazza G.R. Prevalence of Whipple’s disease in north-western Italy. Eur J Clin Microbiol Infect Dis. 2015 Jul;34(7):1347-8. doi: 10.1007/s10096-015-2357-2.

561. Relman D.A., Schmidt T.M., MacDermott R.P., Falkow S. Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med. 1992 Jul 30;327(5):293-301. doi: 10.1056/NEJM199207303270501.

562. Flannagan R.S., Cosío G., Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol. 2009 May;7(5):355-66. doi: 10.1038/nrmicro2128.

563. Johansson M., Lehto M., Tanhuanpää K., Cover T.L., Olkkonen V.M. The oxysterol-binding protein homologue ORP1L interacts with Rab7 and alters functional properties of late endocytic compartments. Mol Biol Cell. 2005 Dec;16(12):5480-92. doi: 10.1091/mbc.e05-03-0189.

564. Papini E., Satin B., Bucci C. et al. The small GTP binding protein rab7 is essential for cellular vacuolation induced by Helicobacter pylori cytotoxin. EMBO J. 1997 Jan 2; 16(1):15-24. doi: 10.1093/emboj/16.1.15.

565. Mottola G., Boucherit N., Trouplin V., Oury Barry A., Soubeyran P., Mege J.L., Ghigo E. Tropheryma whipplei, the agent of Whipple’s disease, affects the early to late phagosome transition and survives in a Rab5- and Rab7-positive compartment. PLoS One. 2014 Feb 24;9(2): e89367. doi: 10.1371/journal.pone.0089367.

566. Marth T., Kleen N., Stallmach A. et al. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple’s disease. Gastroenterology. 2002 Nov;123(5):1468-77. doi: 10.1053/gast.2002.36583.

567. Moos V., Kunkel D., Marth T., Feurle G.E., LaScola B., Ignatius R., Zeitz M., Schneider T. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple’s disease. J Immunol. 2006 Aug 1;177(3):2015-22. doi: 10.4049/jimmunol.177.3.2015.

568. Desnues B., Raoult D., Mege J.L. IL-16 is critical for Tropheryma whipplei replication in Whipple’s disease. J Immunol. 2005 Oct 1;175(7):4575-82. doi: 10.4049/jimmunol.175.7.4575.

569. Le Goff M., Cornec D., Guellec D. et al. Peripheral-blood b-cell subset disturbances in inflammatory joint diseases induced by Tropheryma whipplei. PLoS One. 2019 Feb 27;14(2): e0211536. doi: 10.1371/journal.pone.0211536.

570. Tison A., Preuss P., Leleu C. et al. Rheumatological features of Whipple disease. Sci Rep. 2021 Jun 10;11(1):12278. doi: 10.1038/s41598-021-91671-9.

571. Gobert A.P., Cheng Y., Wang J.Y. et al. Helicobacter pylori induces macrophage apoptosis by activation of arginase II. J Immunol. 2002 May 1;168(9):4692-700. doi: 10.4049/jimmunol.168.9.4692.

572. Moro L., Pomari E., Leonardi M. et al. Tropheryma whipplei, Helicobacter pylori, and Intestinal Protozoal Co-Infections in Italian and Immigrant Populations: A Cross-Sectional Study. Microorganisms. 2022 Apr 2;10(4):769. doi: 10.3390/microorganisms10040769.

573. Scalvini D., Cambieri P., Schiepatti A. et al. Patients with Whipple’s disease have a high prevalence of Helicobacter pylori infection. Eur J Intern Med. 2023 May;111:77-81. doi: 10.1016/j.ejim.2023.02.017.

574. Brown L.M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283-97. doi: 10.1093/oxfordjournals.epirev.a018040.

575. Miyamoto R., Okuda M., Lin Y., Murotani K., Okumura A., Kikuchi S. Rapidly decreasing prevalence of Helicobacter pylori among Japanese children and adolescents. J Infect Chemother. 2019 Jul;25(7):526-530. doi: 10.1016/j.jiac.2019.02.016.

576. Nguyen T.H., Mallepally N., Hammad T., Liu Y., Thrift A.P., El-Serag H.B., Tan M.C. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 Aug;65(8):2403-2411. doi: 10.1007/s10620-019-05955-2.

577. Dore M.P., Marras G., Rocchi C. et al. Changing prevalence of Helicobacter pylori infection and peptic ulcer among dyspeptic Sardinian patients. Intern Emerg Med. 2015 Oct;10(7):787-94. doi: 10.1007/s11739-015-1218-4.

578. Stevenson T.H., Lucia L.M., Acuff G.R. Development of a selective medium for isolation of Helicobacter pylori from cattle and beef samples. Appl Environ Microbiol. 2000 Feb;66(2):723-7. doi: 10.1128/AEM.66.2.723-727.2000.

579. Philippou N., Roussos A., Tsimpoukas F. et al. Helicobacter pylori infection in patients with active pulmonary tuberculosis before the initiation of antituberculosis treatment. Ann. Gastroenterology. 2003;16(1):49-52.

580. Tsang K.W., Lam S.K. Extragastroduodenal conditions associated with Helicobacter pylori infection. Hong Kong Med J. 1999 Jun;5(2):169-174. PMID: 11821587.

581. Martin G., Lazarus A. Epidemiology and diagnosis of tuberculosis. Recognition of at-risk patients is key to prompt detection. Postgrad Med. 2000 Aug;108(2):42-4, 47-50, 53-4. doi: 10.3810/pgm.2000.08.1179.

582. Graham D.Y., Adam E., Reddy G.T. et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991 Aug;36(8):1084-8. doi: 10.1007/BF01297451.

583. Tjarnlund A. Does IgA play a role in protection against pulmonary tuberculosis? Licentiate thesis from the Department of Immunology Wenner-Gren Institute, Stockholm University, Sweden. 2005, 58 p.

584. Azuma T., Konishi J., Tanaka Y., Hirai M., Ito S., Kato T., Kohli Y. Contribution of HLA-DQA gene to host’s response against Helicobacter pylori. Lancet. 1994 Feb 26;343(8896):542-3. doi: 10.1016/s0140-6736(94)91496-6.

585. Goldfeld A.E., Delgado J.C., Thim S. et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA. 1998 Jan 21;279(3):226-8. doi: 10.1001/jama.279.3.226.

586. Durazzo M., Adriani A., Fagoonee S., Saracco G.M., Pellicano R. Helicobacter pylori and Respiratory Diseases: 2021 Update. Microorganisms. 2021 Sep 26;9(10):2033. doi: 10.3390/microorganisms9102033.

587. Perry S., Hussain R., Parsonnet J. The impact of mucosal infections on acquisition and progression of tuberculosis. Mucosal Immunol. 2011 May;4(3):246-51. doi: 10.1038/mi.2011.11.

588. Bustamante-Rengifo J.A., Astudillo-Hernández M., Del Pilar Crespo-Ortiz M. Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis. Curr Microbiol. 2021 Sep;78(9):3351-3371. doi: 10.1007/s00284-021-02604-8.

589. Torres M.A., Passaro D.J., Watanabe J. et al. No association between Helicobacter pylori and Mycobacterium tuberculosis infections among gastrointestinal clinic attendees in Lima, Peru. Epidemiol Infect. 2003 Feb;130(1):87-91. doi: 10.1017/s0950268802007653.

590. Perry S., de Jong B.C., Solnick J.V. et al. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One. 2010 Jan 20;5(1): e8804. doi: 10.1371/journal.pone.0008804.

591. Chuah S.K., Tai W.C., Lee C.H., Liang C.M., Hu T.H. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014;2014:151543. doi: 10.1155/2014/151543.

592. Jeon C.Y., Calver A.D., Victor T.C., Warren R.M., Shin S.S., Murray M.B. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis. 2011 Jan;15(1):77-83. PMID: 21276301.

593. Devasia R.A., Blackman A., Gebretsadik T. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009 Aug 15;180(4):365-70. doi: 10.1164/rccm.200901-0146OC.

594. Mirbagheri S.A., Sohrabpour A.A., Hasibi M., Moghimi B., Mohamadnejad M. 14C-urea breath test in patients undergoing anti-tuberculosis therapy. World J Gastroenterol. 2005 Mar 21;11(11):1712-4. doi: 10.3748/wjg.v11.i11.1712.

595. Sanaka M., Kuyama Y., Yamanaka M., Iwasaki M. Decrease in serum concentrations of Helicobacter pylori IgG antibodies during antituberculosis therapy: the possible eradication by rifampicin and streptomycin. Am J Gastroenterol. 1999 Jul;94(7):1983-4. doi: 10.1111/j.1572-0241.1999.1983a.x.

596. Ribaldone D.G., Fagoonee S., Astegiano M. et al. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. J Clin Med. 2019 Feb 6;8(2):199. doi: 10.3390/jcm8020199.

597. Perri F., Festa V., Clemente R. et al. Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001 Jan;96(1):58-62. doi: 10.1111/j.1572-0241.2001.03452.x.

598. Megraud F., Coenen S., Versporten A. et al.; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013 Jan;62(1):34-42. doi: 10.1136/gutjnl-2012-302254.

599. Gisbert J.P. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens. 2020 Dec 28;10(1):15. doi: 10.3390/pathogens10010015.

600. Gisbert J.P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Jan;35(2):209-21. doi: 10.1111/j.1365-2036.2011.04937.x.

601. Graham D.Y., Canaan Y., Maher J., Wiener G., Hulten K.G., Kalfus I.N. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020 Jun 16;172(12):795-802. doi: 10.7326/M19-3734.

602. Maev I.V., Andreev D.N., Govorun V.M. et al. Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results. Terapevticheskii arkhiv. 2020;92(8):24-28. (in Russ.) doi: 10.26442/00403660.2020.08.000761.@@ Маев И.В., Андреев Д.Н., Говорун В.М. и др. Антибиотикорезистентность Helicobacter pylori в европейской части Российской Федерации: первые результаты. Терапевтический архив. 2020;92(8):24-28. doi: 10.26442/00403660.2020.08.000761.

603. Silver L.L. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011 Jan;24(1):71-109. doi: 10.1128/CMR.00030-10.

604. Rothstein D.M. Rifamycins, Alone and in Combination. Cold Spring Harb Perspect Med. 2016 Jul 1;6(7): a027011. doi: 10.1101/cshperspect.a027011.

605. Bibik O.I., Pomytkina T.E., Pivovar O.I. Study of the peculiarities of combined opisthorchosis and helicobacteriosis. Russian Journal of Parasitology. 2021;15(1):79-84. (In Russ.) doi: 10.31016/1998-8435-2021-15-1-79-84.@@ Бибик О.И., Помыткина Т.Е., Пивовар О.И. Изучение особенностей сочетанного течения описторхоза и хеликобактериоза. Российский паразитологический журнал. 2021;15(1):79-84. doi: 10.31016/1998-8435-2021-15-1-79-84.

606. Pomytkina T. E., Simanovich E.V., Kirsanova D.V. [Mixed infection in patients of the gastroenterology department]. Collection of selected articles based on the materials of scientific conferences of the State Research Institute “Natrazvitie”. 2020, pp. 128-130. (in Russ.)@@ Помыткина Т.Е., Симанович Е.В., Кирсанова Д.В. Микст-инфекция у пациентов гастроэнтерологического отделения. Сборник избранных статей по материалам научных конференций ГНИИ» Нацразвитие». - 2020. - С. 128-130..

607. Nemchenko U.M., Grigorova E.V., Ivanova E.I. et al. Frequency of helicobacter pylori infection and giardiasis in children of different age groups with abdominal pain and dyspeptic syndrome according to the fecal immunochromatographic method. Journal Infectology. 2018;10(1):24-28. (In Russ.) doi: 10.22625/2072-6732-2018-10-1-24-28.@@ Немченко У.М., Григорова Е.В., Иванова Е.И. и др. Частота встречаемости хеликобактериоза и лямблиоза у детей разных возрастных групп с болевым абдоминальным и диспепсическим синдромом по данным исследования кала иммунохроматографическим методом. Журнал инфектологии. 2018;10(1):24-28. doi: 10.22625/2072-6732-2018-10-1-24-28..

608. Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17:50-63. doi: 10.1038/s41423-019-0339-5.

609. Chen L., Xu W., Lee A. et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018 Sep;35:87-96. doi: 10.1016/j.ebiom.2018.08.028.

610. Blaser M.J. Helicobacter pylori and gastric diseases. BMJ. 1998 May 16;316(7143):1507-10. doi: 10.1136/bmj.316.7143.1507..

611. Kononova S., Litvinova E., Vakhitov T., Skalinskaya M., Sitkin S. Acceptive Immunity: The Role of Fucosylated Glycans in Human Host-Microbiome Interactions. Int J Mol Sci. 2021 Apr 8;22(8):3854. doi: 10.3390/ijms22083854.

612. Goto Y., Uematsu S., Kiyono H. Epithelial glycosylation in gut homeostasis and inflammation. Nat Immunol. 2016 Oct 19;17(11):1244-1251. doi: 10.1038/ni.3587..

613. Bravo D., Hoare A., Soto C., Valenzuela M.A., Quest A.F. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018 Jul 28;24(28):3071-3089. doi: 10.3748/wjg.v24.i28.3071..

614. Wang L., Zhou J., Xin Y., Geng C., Tian Z., Yu X., Dong Q. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016 Mar;28(3):261-6. doi: 10.1097/MEG.0000000000000542.

615. Sasaki M., Klapproth J.M. The role of bacteria in the pathogenesis of ulcerative colitis. J Signal Transduct. 2012;2012:704953. doi: 10.1155/2012/704953.

616. Wei P.L., Hung C.S., Kao Y.W. et al. Classification of Changes in the Fecal Microbiota Associated with Colonic Adenomatous Polyps Using a Long-Read Sequencing Platform. Genes (Basel). 2020 Nov 20;11(11):1374. doi: 10.3390/genes11111374.

617. Rath S., Heidrich B., Pieper D.H., Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017 May 15;5(1):54. doi: 10.1186/s40168-017-0271-9.

618. Vasyutin A.V., Tonkikh Yu.L., Tsukanov V.V. Role of Microbiome in Stomach Cancer Development. Doctor.Ru. 2020; 19(7): 49-51. (in Russ.) doi: 10.31550/1727-2378-2020-19-7-49-51.@@ Васютин А.В., Тонких Ю.Л., Цуканов В.В. Роль микробиома в развитии рака желудка. Доктор.Ру. 2020; 19(7): 49-51. doi: 10.31550/1727-2378-2020-19-7-49-51.

619. Sitkin S., Lazebnik L., Avalueva E., Kononova S., Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit-risk approach? World J Gastroenterol. 2022 Feb 21;28(7):766-774. doi: 10.3748/wjg.v28.i7.766.

620. Jaka H., Smith S.I. Forty Years of Helicobacter pylori: The African Perspective. Dig Dis. 2024;42(2):161-165. doi: 10.1159/000535263..

621. Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019 Jan 18;152(2):65-71. English, Spanish. doi: 10.1016/j.medcli.2018.09.006.

622. Choi I.J., Kim C.G., Lee J.Y., Kim Y.I., Kook M.C., Park B., Joo J. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med. 2020 Jan 30;382(5):427-436. doi: 10.1056/NEJMoa1909666.

623. Wiklund A.K., Santoni G., Yan J. et al. Risk of Esophageal Adenocarcinoma After Helicobacter pylori Eradication Treatment in a Population-Based Multinational Cohort Study. Gastroenterology. 2024 Aug;167(3):485-492.e3. doi: 10.1053/j.gastro.2024.03.016.

624. Katelaris P., Hunt R., Bazzoli F. et al. Helicobacter pylori World Gastroenterology Organization Global Guideline. J Clin Gastroenterol. 2023 Feb 1;57(2):111-126. doi: 10.1097/MCG.0000000000001719..

625. Marchenko S.V., Dotsenko Yu.N. Enteral nutrition in intensive care. Gomel: State Institution "RSPC RMIEC", 2019. 49 p. (in Russ.)@@ Марченко С.В. Энтеральное питание в интенсивной терапии. С.В. Марченко, Ю.Н. Доценко - Гомель: ГУ «РНПЦ РМиЭЧ», 2019. -49 с.

626. Tutelyan V. A., Samsonov M.A. Handbook of Dietetics. Moscow. Medicine, 2002. 544 p. (in Russ.)@@ Тутельян В. А., Самсонов М.А. Справочник по диетологии - М.: Медицина, 2002. - 544 с.